10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)
☑	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended March 31, 2023
	OR
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from     to

Commission file number: 001-11993

OPTION CARE HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware				05-0489664
(State of incorporation)				(I.R.S. Employer Identification No.)
3000 Lakeside Dr.	Suite 300N,	Bannockburn,	IL	60015
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code:

312-940-2443

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	OPCH	Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☑     No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☑     Accelerated filer ☐     Non-accelerated filer ☐      Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐     No ☑  

On May 2, 2023, there were 179,764,281 shares of the registrant’s Common Stock outstanding.

1

TABLE OF CONTENTS

		Page Number
PART I
Item 1.	Financial Statements	5
	Condensed Consolidated Balance Sheets	6
	Unaudited Condensed Consolidated Statements of Comprehensive Income	7
	Unaudited Condensed Consolidated Statements of Cash Flows	8
	Unaudited Condensed Consolidated Statements of Stockholders’ Equity	9
	Notes to Unaudited Condensed Consolidated Financial Statements	10
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	33
Item 4.	Controls and Procedures	33
PART II
Item 1.	Legal Proceedings	34
Item 1A.	Risk Factors	34
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	34
Item 6.	Exhibits	35
SIGNATURES		35

3

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q (this “Form 10-Q”) to "Option Care Health," the “Company,” “we,” “us” and “our” refer to Option Care Health, Inc. and its consolidated subsidiaries.

Forward-Looking Statements

This Form 10-Q includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning our expectations regarding industry and macroeconomic trends and our operating performance. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. If any of these risks materialize, or if any of our assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, those set forth in Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2022 (our “Form 10-K”) filed with the U.S. Securities and Exchange Commission (the “SEC”). Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this Form 10-Q. Any forward-looking statement made by us in this Form 10-Q speaks only as of the date hereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

4

PART I

FINANCIAL INFORMATION

Item 1.Financial Statements

5

OPTION CARE HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS)

	March 31, 2023		December 31, 2022
	(unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	297,776	$	294,186
Accounts receivable, net	395,209		377,542
Inventories	249,643		224,281
Prepaid expenses and other current assets	86,908		98,330
Total current assets	1,029,536		994,339
NONCURRENT ASSETS:
Property and equipment, net	105,571		108,321
Operating lease right-of-use asset	70,077		72,424
Intangible assets, net	21,677		22,371
Referral sources, net	334,001		341,744
Goodwill	1,533,569		1,533,424
Other noncurrent assets	35,971		40,313
Total noncurrent assets	2,100,866		2,118,597
TOTAL ASSETS	$	3,130,402	$	3,112,936
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable	$	448,890	$	378,763
Accrued compensation and employee benefits	48,550		76,906
Accrued expenses and other current liabilities	96,279		84,302
Current portion of operating lease liability	18,847		19,380
Current portion of long-term debt	6,000		6,000
Total current liabilities	618,566		565,351
NONCURRENT LIABILITIES:
Long-term debt, net of discount, deferred financing costs and current portion	1,057,787		1,058,204
Operating lease liability, net of current portion	69,961		71,441
Deferred income taxes	30,780		22,154
Other noncurrent liabilities	3,089		9,683
Total noncurrent liabilities	1,161,617		1,161,482
Total liabilities	1,780,183		1,726,833
STOCKHOLDERS’ EQUITY:
Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of March 31, 2023 and December 31, 2022, respectively	—		—
Common stock; $0.0001 par value: 250,000,000 shares authorized, 182,615,601 shares issued and 179,756,714 shares outstanding as of March 31, 2023; 182,341,420 shares issued and 181,957,698 shares outstanding as of December 31, 2022	18		18
Treasury stock; 2,858,887 and 383,722 shares outstanding, at cost, as of March 31, 2023 and December 31, 2022, respectively	(78,138)		(2,403)
Paid-in capital	1,180,992		1,176,906
Retained earnings	229,631		190,423
Accumulated other comprehensive income	17,716		21,159
Total stockholders’ equity	1,350,219		1,386,103
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	3,130,402	$	3,112,936

The notes to unaudited condensed consolidated financial statements are an integral part of these statements.

6

OPTION CARE HEALTH, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

	Three Months Ended March 31,
	2023		2022
NET REVENUE	$	1,015,848	$	915,784
COST OF REVENUE	786,843		714,848
GROSS PROFIT	229,005		200,936
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses	147,866		133,969
Depreciation and amortization expense	14,514		14,722
Total operating expenses	162,380		148,691
OPERATING INCOME	66,625		52,245
OTHER INCOME (EXPENSE):
Interest expense, net	(13,834)		(12,246)
Equity in earnings of joint ventures	1,437		1,267
Other, net	1		2
Total other expense	(12,396)		(10,977)
INCOME BEFORE INCOME TAXES	54,229		41,268
INCOME TAX EXPENSE	15,021		10,993
NET INCOME	$	39,208	$	30,275
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $1,152 and ($3,763), respectively	$	(3,443)	$	11,070
OTHER COMPREHENSIVE (LOSS) INCOME	(3,443)		11,070
NET COMPREHENSIVE INCOME	$	35,765	$	41,345
EARNINGS PER COMMON SHARE:
Earnings per share, basic	$	0.22	$	0.17
Earnings per share, diluted	$	0.21	$	0.17
Weighted average common shares outstanding, basic	181,262		179,961
Weighted average common shares outstanding, diluted	182,735		181,681

The notes to unaudited condensed consolidated financial statements are an integral part of these statements.

7

OPTION CARE HEALTH, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

	Three Months Ended March 31,
	2023		2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	39,208	$	30,275
Adjustments to reconcile net income to net cash provided by operations:
Depreciation and amortization expense	15,225		15,979
Non-cash operating lease costs	5,540		3,884
Deferred income taxes - net	8,626		12,996
Amortization of deferred financing costs	1,083		1,049
Equity in earnings of joint ventures	(1,437)		(1,267)
Stock-based incentive compensation expense	5,988		4,178
Capital distribution from equity method investments	2,500		—
Other adjustments	198		291
Changes in operating assets and liabilities:
Accounts receivable, net	(17,812)		(28,766)
Inventories	(25,362)		(34,089)
Prepaid expenses and other current assets	9,977		(6,241)
Accounts payable	70,127		76,872
Accrued compensation and employee benefits	(28,356)		(41,481)
Accrued expenses and other current liabilities	14,831		13,520
Operating lease liabilities	(5,271)		(4,246)
Other noncurrent assets and liabilities	(5,313)		(10,273)
Net cash provided by operating activities	89,752		32,681
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment	(5,760)		(5,359)
Net cash used in investing activities	(5,760)		(5,359)
CASH FLOWS FROM FINANCING ACTIVITIES:
Exercise of stock options, vesting of restricted stock, and related tax withholdings	(1,902)		355
Repayments of debt principal	(1,500)		(1,500)
Purchase of company stock	(75,000)		—
Other financing activities	(2,000)		—
Net cash used in financing activities	(80,402)		(1,145)
NET INCREASE IN CASH AND CASH EQUIVALENTS	3,590		26,177
Cash and cash equivalents - beginning of the period	294,186		119,423
CASH AND CASH EQUIVALENTS - END OF PERIOD	$	297,776	$	145,600
Supplemental disclosure of cash flow information:
Cash paid for interest	$	11,161	$	5,104
Cash paid for income taxes	$	—	$	61
Cash paid for operating leases	$	6,527	$	6,242

The notes to unaudited condensed consolidated financial statements are an integral part of these statements.

8

Table of Contents

OPTION CARE HEALTH, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(IN THOUSANDS)

	Preferred Stock		Common Stock		Treasury Stock		Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive (Loss) Income		Total Stockholders’ Equity
Balance - December 31, 2021	$	—	$	18	$	(2,403)	$	1,138,855	$	39,867	$	(451)	$	1,175,886
Exercise of stock options, vesting of restricted stock, and related tax withholdings	—		—		—		355		—		—		355
Stock-based incentive compensation	—		—		—		4,178		—		—		4,178
Net income	—		—		—		—		30,275		—		30,275
Other comprehensive income	—		—		—		—		—		11,070		11,070
Balance - March 31, 2022	$	—	$	18	$	(2,403)	$	1,143,388	$	70,142	$	10,619	$	1,221,764
Balance - December 31, 2022	$	—	$	18	$	(2,403)	$	1,176,906	$	190,423	$	21,159	$	1,386,103
Exercise of stock options, vesting of restricted stock, and related tax withholdings	—		—		—		(1,902)		—		—		(1,902)
Stock-based incentive compensation	—		—		—		5,988		—		—		5,988
Purchase of company stock	—		—		(75,735)		—		—		—		(75,735)
Net income	—		—		—		—		39,208		—		39,208
Other comprehensive loss	—		—		—		—		—		(3,443)		(3,443)
Balance - March 31, 2023	$	—	$	18	$	(78,138)	$	1,180,992	$	229,631	$	17,716	$	1,350,219

The notes to unaudited condensed consolidated financial statements are an integral part of these statements.

9

Table of Contents

OPTION CARE HEALTH, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS

Corporate Organization and Business — HC Group Holdings II, Inc. (“HC II”) was incorporated under the laws of the State of Delaware on January 7, 2015, with its sole shareholder being HC Group Holdings I, LLC. (“HC I”). On April 7, 2015, HC I and HC II collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care, Inc. (“Option Care”).

On March 14, 2019, HC I and HC II entered into a definitive agreement (the “Merger Agreement”) to merge with and into a wholly-owned subsidiary of BioScrip, Inc. (“BioScrip”) (the “Merger”), a national provider of infusion and home care management solutions, which was completed on August 6, 2019 (the “Merger Date”). Following the close of the transaction, BioScrip was rebranded as Option Care Health. The combined Company’s stock is listed on the Nasdaq Global Select Market as of March 31, 2023. During the three months ended March 31, 2023, HC I completed a secondary offering of 13,000,000 shares of common stock. In addition to this secondary offering, the Company repurchased 2,475,166 shares from HC I on March 3, 2023 under the Company’s share repurchase program. See Note 15, Stockholders’ Equity, for further discussion of the Company’s share repurchase program. Following these transactions, HC I holds approximately 6% of the common stock of the Company.

Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 95 full service pharmacies and 73 stand-alone ambulatory infusion suites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services.

Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2022 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.

Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.

The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the unaudited condensed consolidated statements of comprehensive income. See Equity-Method Investments within Note 2, Summary of Significant Accounting Policies, for further discussion of the Company’s equity-method investments.

10

Table of Contents

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March 31, 2023, cash equivalents consisted of money market funds.

Prepaid Expenses and Other Current Assets — Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $48.3 million and $53.4 million as of March 31, 2023 and December 31, 2022, respectively.

Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March 31, 2023 and December 31, 2022, the balance of the investments was $18.3 million and $19.4 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.4 million and $1.3 million for the three months ended March 31, 2023 and 2022, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March 31, 2023, the Company received a distribution of $2.5 million from the investees. During the three months ended March 31, 2022, the Company did not receive a distribution from the investees. See Note 16, Related-Party Transactions, for discussion of related-party transactions with these investees.

Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 14% and 15% for the three months ended March 31, 2023 and 2022, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.

For the three months ended March 31, 2023 and 2022, approximately 12% and 13%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. As of March 31, 2023 and December 31, 2022, approximately 11% and 13%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.

The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.

For the three months ended March 31, 2023 and 2022, approximately 72% and 75%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results. Although there remains some uncertainty regarding the COVID-19 pandemic, as of March 31, 2023, the Company has been able to maintain adequate levels of supplies and pharmaceuticals to support its operations.

11

Table of Contents

3. BUSINESS COMBINATIONS

Rochester Home Infusion, Inc. — In August 2022, pursuant to the stock purchase agreement dated June 10, 2022, the Company completed the acquisition of 100% of the equity interests in Rochester Home Infusion, Inc. (“RHI”) for a purchase price, net of cash acquired, of $27.4 million.

The allocation of the purchase price of RHI was accounted for as a business combination in accordance with ASC Topic 805, Business Combinations, with the total purchase price being allocated to the assets and liabilities acquired based on the relative fair value of each asset and liability. The following is a final allocation of the consideration transferred to acquired identifiable assets and assumed liabilities, net of cash acquired, as of March 31, 2023 (in thousands):

	Amount
Accounts receivable	$	686
Intangible assets	5,449
Other assets	394
Accounts payable and other liabilities	(434)
Fair value identifiable assets and liabilities	6,095
Goodwill (1)	21,323
Cash acquired	201
Purchase price	27,619
Less: cash acquired	(201)
Purchase price, net of cash acquired	$	27,418

(1) Goodwill is attributable to cost synergies from procurement and operational efficiencies and elimination of duplicative administrative costs.

12

Table of Contents

4. REVENUE

The following table sets forth the net revenue earned by category of payer for the three months ended March 31, 2023 and 2022 (in thousands):

	Three Months Ended March 31,
	2023		2022
Commercial payers	$	873,911	$	786,278
Government payers	122,789		115,205
Patients	19,148		14,301
Net revenue	$	1,015,848	$	915,784

5. INCOME TAXES

During the three months ended March 31, 2023 and 2022, the Company recorded tax expense of $15.0 million and $11.0 million, respectively, which represents an effective tax rate of 27.7% and 26.6%, respectively. The variance in the Company’s effective tax rate of 27.7% for the three months ended March 31, 2023, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, as well as various non-deductible expenses. The variance in the Company’s effective tax rate of 26.6% for the three months ended March 31, 2022, compared to the federal statutory rate of 21%, is primarily attributable to current and deferred state taxes as well as various non-deductible expenses.

The Company maintains a valuation allowance of $13.1 million against certain state net operating losses. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. In making this assessment, the Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income, and tax-planning strategies. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.

The Company’s tax expense for the three months ended March 31, 2023 of $15.0 million consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense. The Company’s tax expense for the three months ended March 31, 2022 of $11.0 million consists of quarterly tax liabilities attributed to specific state taxing authorities as well as recognized deferred federal and state tax expense.

The Company has accumulated federal net operating loss carryovers that are subject to one or more Section 382 limitations. This may limit the Company’s ability to utilize its federal net operating losses.

13

Table of Contents

6. EARNINGS PER SHARE

The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.

The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three months ended March 31, 2023 and 2022 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods. As of March 31, 2023, there were 871,491 stock option awards, 342,894 restricted stock awards and 90,159 performance stock unit awards outstanding that were excluded from the calculation of earnings per share as they would be anti-dilutive. As of March 31, 2022, there were 457,752 warrants, 770,303 stock option awards, and 269,670 restricted stock awards outstanding that were excluded from the calculation of earnings per share as they would be anti-dilutive.

The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):

	Three Months Ended March 31,
	2023		2022
Numerator:
Net income	$	39,208	$	30,275
Denominator:
Weighted average number of common shares outstanding	181,262		179,961
Earnings per common share:
Earnings per common share, basic	$	0.22	$	0.17

The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):

	Three Months Ended March 31,
	2023		2022
Numerator:
Net income	$	39,208	$	30,275
Denominator:
Weighted average number of common shares outstanding	181,262		179,961
Effect of dilutive securities	1,473		1,720
Weighted average number of common shares outstanding, diluted	182,735		181,681
Earnings per common share:
Earnings per common share, diluted	$	0.21	$	0.17

,

14

Table of Contents

7. LEASES

During the three months ended March 31, 2023 and 2022, the Company incurred operating lease expenses of $7.0 million and $7.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March 31, 2023, the weighted-average remaining lease term was 6.4 years and the weighted-average discount rate was 5.38%.

Operating leases mature as follows (in thousands):

Fiscal Year Ended December 31,	Minimum Payments
2023	$	20,721
2024	18,973
2025	16,254
2026	13,537
2027	11,451
Thereafter	27,733
Total lease payments	108,669
Less: interest	(19,861)
Present value of lease liabilities	$	88,808

During the three months ended March 31, 2023, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow of $3.3 million related to increases in the operating lease right-of-use assets and operating lease liabilities, respectively. As of March 31, 2023, the Company did not have any significant operating or financing leases that had not yet commenced.

15

Table of Contents

8. PROPERTY AND EQUIPMENT

Property and equipment was as follows as of March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Infusion pumps	$	35,500	$	34,942
Equipment, furniture and other	35,156		31,929
Leasehold improvements	99,639		99,085
Computer software, purchased and internally developed	44,035		34,922
Assets under development	18,992		29,411
	233,322		230,289
Less: accumulated depreciation	(127,751)		(121,968)
Property and equipment, net	$	105,571	$	108,321

Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March 31, 2023 and 2022 (in thousands):

	Three Months Ended March 31,
	2023		2022
Depreciation expense in cost of revenue	$	711	$	1,257
Depreciation expense in operating expenses	6,012		7,188
Total depreciation expense	$	6,723	$	8,445

16

Table of Contents

9. GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill consists of the following activity for the three months ended March 31, 2023 (in thousands):

Balance at December 31, 2022	$	1,533,424
Purchase accounting adjustments	145
Balance at March 31, 2023	$	1,533,569

The carrying amount and accumulated amortization of intangible assets consist of the following as of March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Gross intangible assets:
Referral sources	$	509,646	$	509,646
Trademarks/names	38,508		38,508
Other amortizable intangible assets	912		912
Total gross intangible assets	549,066		549,066
Accumulated amortization:
Referral sources	(175,645)		(167,902)
Trademarks/names	(17,548)		(16,901)
Other amortizable intangible assets	(195)		(148)
Total accumulated amortization	(193,388)		(184,951)
Total intangible assets, net	$	355,678	$	364,115

Amortization expense for intangible assets was $8.5 million and $7.5 million for the three months ended March 31, 2023 and 2022, respectively.

17

Table of Contents

10. INDEBTEDNESS

Long-term debt consisted of the following as of March 31, 2023 (in thousands):

	Principal Amount		Discount		Debt Issuance Costs		Net Balance
Asset-based-lending (“ABL”) Facility	$	—	$	—	$	—	$	—
First Lien Term Loan	592,500		(7,982)		(11,077)		573,441
Senior Notes	500,000		—		(9,654)		490,346
	$	1,092,500	$	(7,982)	$	(20,731)	1,063,787
Less: current portion							(6,000)
Total long-term debt							$	1,057,787

Long-term debt consisted of the following as of December 31, 2022 (in thousands):

	Principal Amount		Discount		Debt Issuance Costs		Net Balance
ABL Facility	$	—	$	—	$	—	$	—
First Lien Term Loan	594,000		(8,307)		(11,529)		574,164
Senior Notes	500,000		—		(9,960)		490,040
	$	1,094,000	$	(8,307)	$	(21,489)	1,064,204
Less: current portion							(6,000)
Total long-term debt							$	1,058,204

The interest rate on the First Lien Term Loan was 7.38% and 6.82% as of March 31, 2023 and December 31, 2022, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 7.28% and 3.25% for the three months ended March 31, 2023 and 2022, respectively. The interest rate on the Senior Notes was 4.375% as of March 31, 2023 and December 31, 2022. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three months ended March 31, 2023 and 2022.

Long-term debt matures as follows (in thousands):

Fiscal Year Ended December 31,	Minimum Payments
2023	$	4,500
2024	6,000
2025	6,000
2026	6,000
2027	6,000
Thereafter	1,064,000
Total	$	1,092,500

During the three months ended March 31, 2023 and 2022, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 11, Derivative Instruments, for further discussion.

The following table presents the estimated fair values of the Company’s debt obligations as of March 31, 2023 (in thousands):

Financial Instrument	Carrying Value as of March 31, 2023		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
First Lien Term Loan	$	573,441	$	—	$	590,278	$	—
Senior Notes	490,346		—		441,250		—
Total debt instruments	$	1,063,787	$	—	$	1,031,528	$	—

See Note 12, Fair Value Measurements, for further discussion.

18

Table of Contents

Effective January 13, 2023, the Company entered into an agreement to amend the ABL Facility, to among other things, increase the amount of borrowing availability by $50.0 million to $225.0 million total borrowing availability and to replace LIBOR with Secured Overnight Financing Rate (“SOFR”) as the new reference rate.

19

Table of Contents

11. DERIVATIVE INSTRUMENTS

The Company uses derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to increases in interest rates related to its variable interest rate debt. Use of derivative financial instruments in hedging programs subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. In a hedging relationship, the change in the value of the derivative financial instrument is offset to a great extent by the change in the value of the underlying hedged item. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.

In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300 million for a 5-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan’s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.

The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):

	Fair Value - Derivatives in Asset Position
Derivative	Balance Sheet Caption	March 31, 2023		December 31, 2022
Interest rate cap designated as cash flow hedge	Prepaid expenses and other current assets	$	9,939	$	10,926
Interest rate cap designated as cash flow hedge	Other noncurrent assets	13,734		17,342
Total derivative assets		$	23,673	$	28,268

The gain (loss) associated with the change in the fair value of the effective portion of the hedging instrument is recorded in other comprehensive (loss) income. The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):

	Three Months Ended March 31,
Derivative	2023		2022
Interest rate cap designated as cash flow hedge	$	(4,595)	$	14,833

The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):

		Three Months Ended March 31,
Derivative	Income Statement Caption	2023		2022
Interest rate cap designated as cash flow hedge	Interest expense, net	$	2,352	$	694

20

Table of Contents

12. FAIR VALUE MEASUREMENTS

Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:

•Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.

•Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.

•Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.

While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.

Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.

Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, Derivative Instruments, for further discussion of the fair value of the interest rate cap.

Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).

There were no other assets or liabilities measured at fair value at March 31, 2023 and December 31, 2022.

13. COMMITMENTS AND CONTINGENCIES

The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.

The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s condensed consolidated balance sheets.

However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.

21

Table of Contents

14. STOCK-BASED INCENTIVE COMPENSATION

Equity Incentive Plans — Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the BioScrip stockholders on May 3, 2018 and amended and restated on May 19, 2021, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors, resulting in a total of 9,101,734 shares of common stock authorized for issuance. The 2018 Plan is administered by the Company’s Compensation Committee, a standing committee of the Company’s Board of Directors. The Company had stock options, restricted stock units and performance stock units outstanding related to the 2018 Plan as of March 31, 2023 and 2022. During the three months ended March 31, 2023 and 2022, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $6.0 million and $4.2 million.

15. STOCKHOLDERS’ EQUITY

2017 Warrants — During the three months ended March 31, 2023 and 2022, warrant holders did not elect to exercise any warrants to purchase shares of common stock. As of March 31, 2023 and December 31, 2022, the remaining warrant holders are entitled to purchase 240,188 shares of common stock.

2015 Warrants — During the three months ended March 31, 2023 and 2022, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. As of March 31, 2023 and December 31, 2022, the remaining warrant holders are entitled to purchase 15,219 and 15,231 shares of common stock, respectively.

Share Repurchase Program — On February 20, 2023, the Company’s Board of Directors approved a share repurchase program of up to an aggregate $250.0 million of common stock of the Company. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.

On March 3, 2023, the Company purchased 2,475,166 shares of common stock under the share repurchase program for an average share price of $30.30, totaling $75.0 million, which repurchased shares became treasury stock. As of March 31, 2023, the Company is authorized to repurchase up to an aggregate $175.0 million of common stock of the Company.

16. RELATED-PARTY TRANSACTIONS

Transactions with Equity-Method Investees — The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $1.3 million and $0.9 million for the three months ended March 31, 2023 and 2022, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income. During the three months ended March 31, 2023, the Company received distributions from the investees of $2.5 million. During the three months ended March 31, 2022, the Company did not receive a distribution from the investees.

The Company had amounts due from its joint ventures of $0.7 million and due to its joint ventures of $0.5 million as of March 31, 2023. Receivables were included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. The Company also had amounts due to its joint ventures of $1.5 million as of December 31, 2022. These payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.

Share Repurchase Agreement — On February 28, 2023, we entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) with HC I, pursuant to which we agreed to repurchase, subject to the terms and conditions contained therein, up to $75.0 million of our common stock then held by HC I at the same purchase price per share as the underwriter in a concurrent underwritten public offering of our common stock held by HC I. On March 3, 2023, the transactions contemplated by the Share Repurchase Agreement closed, and we repurchased directly from HC I 2,475,166 shares of our common stock.

17. SUBSEQUENT EVENTS

On May 3, 2023 the Company entered into a definitive merger agreement with Amedisys, Inc. (“Amedisys”), a leading provider of healthcare in home health and hospice settings. Under the terms of the merger agreement, the Company will issue new shares of its common stock to Amedisys’s stockholders, which will result in the Company’s stockholders holding

22

Table of Contents

approximately 64.5% of the combined company. Following the close of the transaction, the combined company common stock is expected to continue to be listed on the Nasdaq Global Select Market. The transaction is currently expected to close in the second half of 2023, subject to approval by the Company’s and Amedisys’s stockholders and other customary closing conditions, including receipt of applicable regulatory approvals.

In connection with its entry into the merger agreement, the Company entered into a debt commitment letter, dated as of May 3, 2023, with Goldman Sachs Bank USA ("Goldman Sachs"), pursuant to which Goldman Sachs has committed to provide a 364-day senior secured term loan facility in an aggregate principal amount of up to $450 million (the "Bridge Loan Facility"), subject to customary conditions as set forth therein. The debt commitment letter provides for a single borrowing of non-amortizing terms loans under such Bridge Loan Facility in an amount up to $450.0 million, which term loans would mature on the date that is 364 days following execution of the definition documentation in respect thereof. The net proceeds of the Bridge Loan Facility may be used to refinance existing indebtedness of Amedisys and to pay related fees and expenses.

23

Table of Contents

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

Unless the context requires otherwise, references in this report to "Option Care Health," the “Company,” “we,” “us” and “our” refer to Option Care Health, Inc. and its consolidated subsidiaries. Management’s discussion and analysis of financial condition and results of operations (“MD&A”) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial condition. The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements and the related notes thereto included in Item 1 of Part I of this Quarterly Report on Form 10-Q (this “Form 10-Q”). Certain statements in this Item 2 of Part I of this Form 10-Q, and in Item 1A, “Risk Factors” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2022 (our “Form 10-K”), may cause our actual results, financial position, and cash and cash equivalents generated from operations to differ materially from these forward-looking statements.

Business Overview

Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 168 locations around the United States. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. Our services are provided in coordination with, and under the direction of, the patient’s physician. Our multidisciplinary team of clinicians, including pharmacists, nurses, and dietitians work with the physician to develop a plan of care suited to each patient’s specific needs. We provide home infusion services consisting of anti-infectives, nutrition support, bleeding disorder therapies, immunoglobulin therapy, and other therapies for chronic and acute conditions.

On April 7, 2015, HC I and HC II collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care.

On March 14, 2019, HC I and HC II entered into the Merger Agreement to merge with and into a wholly-owned subsidiary of BioScip, a national provider of infusion and home care management solutions, which was completed on August 6, 2019. Following the close of the transaction, BioScrip was rebranded as Option Care Health.

24

Table of Contents

Update on the Impact of the COVID-19 Pandemic

The primary operations of the Company focus on providing infusion therapy services, however, the COVID-19 pandemic has impacted the healthcare ecosystem and the Company such that, beginning in March 2020, we have been disrupted by both positive and negative referral patterns and have experienced challenges in our staffing, increased pricing and periodic inability to procure personal protection equipment, supplies and key drugs. The Company anticipates that new variants could affect its operations for an extended period; however, at this time we cannot confidently forecast the duration or the ultimate financial impact on our operations.

See Item 1A. “Risk Factors” under the caption “The COVID-19 pandemic and other potential pandemic events could adversely impact our business, results of operations, cash flows and financial position” included in our Form 10-K for further discussion of risks.

25

Table of Contents

Composition of Results of Operations

The following results of operations include the accounts of Option Care Health and our subsidiaries for the three months ended March 31, 2023 and 2022.

Gross Profit

Gross profit represents our net revenue less cost of revenue.

Net Revenue. Infusion and related health care services revenue is reported at the estimated net realizable amounts from third-party payers and patients for goods sold and services rendered. When pharmaceuticals are provided to a patient, revenue is recognized upon delivery of the goods. When nursing services are provided, revenue is recognized when the services are rendered.

Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in adjustments to amounts originally recorded.

Cost of Revenue. Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients. In addition to product costs, cost of revenue includes warehousing costs, purchasing costs, depreciation expense relating to revenue-generating assets, such as infusion pumps, shipping and handling costs, and wages and related costs for the pharmacists, nurses, and all other employees and contracted workers directly involved in providing service to the patient.

The Company receives volume-based rebates and prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These payments are recorded as a reduction of inventory and are accounted for as a reduction of cost of revenue when the related inventory is sold.

Operating Costs and Expenses

Selling, General and Administrative Expenses. Selling, general and administrative expenses consist principally of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.

Depreciation and Amortization Expense. Depreciation within this caption includes infrastructure items such as intangibles amortization, computer hardware and software, office equipment and leasehold improvements. Depreciation of revenue-generating assets, such as infusion pumps, is included in cost of revenue.

Other Income (Expense)

Interest Expense, Net. Interest expense consists principally of interest payments on the Company’s outstanding borrowings under the ABL Facility, First Lien Term Loan, Senior Notes, amortization of discount and deferred financing fees, payments associated with the interest rate cap, and interest income earned on cash and cash equivalents. Refer to the “Liquidity and Capital Resources” section below for further discussion of these outstanding borrowings.

Equity in Earnings of Joint Ventures. Equity in earnings of joint ventures consists of our proportionate share of equity earnings or losses from equity investments in two infusion joint ventures with health systems.

Other, Net. Other income (expense) primarily includes activity related to non-operating income and expenses.

Income Tax Expense. The Company is subject to taxation in the United States and various states. The Company’s income tax expense is reflective of the current federal and state tax rates.

Change in Unrealized (Losses) Gains on Cash Flow Hedges, Net of Income Tax Expense. Change in unrealized (losses) gains on cash flow hedges, net of income taxes, consists of the gains and losses associated with the changes in the fair value of derivatives designated as hedging instruments related to the interest rate cap hedge, net of income taxes.

26

Table of Contents

Results of Operations

The following table presents Option Care Health’s consolidated results of operations for the three months ended March 31, 2023 and 2022 (in thousands, except for percentages):

	Three Months Ended March 31,
	2023				2022
	Amount		% of Revenue		Amount		% of Revenue
NET REVENUE	$	1,015,848	100.0	%	$	915,784	100.0	%
COST OF REVENUE	786,843		77.5	%	714,848		78.1	%
GROSS PROFIT	229,005		22.5	%	200,936		21.9	%
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses	147,866		14.6	%	133,969		14.6	%
Depreciation and amortization expense	14,514		1.4	%	14,722		1.6	%
Total operating expenses	162,380		16.0	%	148,691		16.2	%
OPERATING INCOME	66,625		6.6	%	52,245		5.7	%
OTHER INCOME (EXPENSE):
Interest expense, net	(13,834)		(1.4)	%	(12,246)		(1.3)	%
Equity in earnings of joint ventures	1,437		0.1	%	1,267		0.1	%
Other, net	1		—	%	2		—	%
Total other expense	(12,396)		(1.2)	%	(10,977)		(1.2)	%
INCOME BEFORE INCOME TAXES	54,229		5.3	%	41,268		4.5	%
INCOME TAX EXPENSE	15,021		1.5	%	10,993		1.2	%
NET INCOME	$	39,208	3.9	%	$	30,275	3.3	%
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $1,152 and ($3,763), respectively	(3,443)		(0.3)	%	11,070		1.2	%
OTHER COMPREHENSIVE (LOSS) INCOME	(3,443)		(0.3)	%	11,070		1.2	%
NET COMPREHENSIVE INCOME	$	35,765	3.5	%	$	41,345	4.5	%

27

Table of Contents

Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022

The following tables present selected consolidated comparative results of operations from Option Care Health’s unaudited condensed consolidated financial statements for the three months ended March 31, 2023 and 2022.

Gross Profit

	Three Months Ended March 31,
	2023			2022			Variance
	(in thousands, except for percentages)
Net revenue	$	1,015,848		$	915,784		$	100,064	10.9	%
Cost of revenue	786,843			714,848			71,995		10.1	%
Gross profit	$	229,005		$	200,936		$	28,069	14.0	%
Gross profit margin	22.5		%	21.9		%

The increase in net revenue was primarily driven by organic growth in the Company’s portfolio of therapies, consisting of acute revenue that had mid-single-digit growth relative to the prior year while chronic revenue grew in the low-double-digits. Acute growth was driven primarily due to collaborating with referral sources, which increased the volume of patient services. Acquisition related growth accounted for approximately 1% of the increase in both net revenue and gross profit. The increase in net revenue was partially offset by the divestiture of respiratory therapy assets as well as therapies related to the treatment of ALS and pre-term labor. The increase in cost of revenue and gross profit was primarily driven by the growth in revenue. Revenue growth outpaced the increase in cost of revenue primarily due to our disciplined procurement strategies and efficient utilization of our infusion suite network, partially offset by inflationary impacts.

Operating Expenses

	Three Months Ended March 31,
	2023		2022		Variance
	(in thousands, except for percentages)
Selling, general and administrative expenses	$	147,866	$	133,969	$	13,897	10.4	%
Depreciation and amortization expense	14,514		14,722		(208)		(1.4)	%
Total operating expenses	$	162,380	$	148,691	$	13,689	9.2	%

The increase in selling, general and administrative expenses is primarily due to an increase in salaries and benefits as a result of acquired team members and inflationary pressures, however, these expenses have remained consistent as a percentage of revenue at 14.6% for the three months ended March 31, 2023 and 2022 due to the Company’s focus on controlling spending leverage.

28

Table of Contents

Other Income (Expense)

	Three Months Ended March 31,
	2023		2022		Variance
	(in thousands, except for percentages)
Interest expense, net	$	(13,834)	$	(12,246)	$	(1,588)	13.0	%
Equity in earnings of joint ventures	1,437		1,267		170		13.4	%
Other, net	1		2		(1)		(50.0)	%
Total other expense	$	(12,396)	$	(10,977)	$	(1,419)	12.9	%

The increase in interest expense, net during the three months ended March 31, 2023 was primarily attributable to increases in the First Lien Term Loan’s variable interest rate as compared to three months ended March 31, 2022, partially offset by interest income generated from our cash and cash equivalents. See Note 10, Indebtedness, of the consolidated financial statements for further information.

The increase in equity in earnings of joint ventures was primarily attributable to the performance of the joint ventures.

Income Tax Expense

	Three Months Ended March 31,
	2023		2022		Variance
	(in thousands, except for percentages)
Income tax expense	$	15,021	$	10,993	$	4,028	36.6	%

The Company recorded income tax expense of $15.0 million and $11.0 million for the three months ended March 31, 2023 and 2022, respectively, which represents an effective tax rate of 27.7% and 26.6%, respectively. The variance in the Company’s effective tax rate of 27.7% for the three months ended March 31, 2023, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, as well as various non-deductible expenses. The variance in the Company’s effective tax rate of 26.6% for the three months ended March 31, 2022, compared to the federal statutory rate of 21%, is primarily attributable to current and deferred state taxes as well as various non-deductible expenses.

29

Table of Contents

Net Income and Other Comprehensive (Loss) Income

	Three Months Ended March 31,
	2023		2022		Variance
	(in thousands, except for percentages)
Net income	$	39,208	$	30,275	$	8,933	29.5	%
Other comprehensive (loss) income, net of tax:
Changes in unrealized (loss) gain on cash flow hedges, net of income taxes	(3,443)		11,070		(14,513)		(131.1)	%
Other comprehensive (loss) income	(3,443)		11,070		(14,513)		(131.1)	%
Net comprehensive income	$	35,765	$	41,345	$	(5,580)	(13.5)	%

The change in net income was primarily attributable to organic growth from additional revenue related to the factors described in the above sections.

For the three months ended March 31, 2023 and 2022, the change in unrealized (loss) gain on cash flow hedges, net of income taxes, was related to the change in fair market value of the $300.0 million interest rate cap hedge executed in October 2021.

Net comprehensive income decreased to $35.8 million for the three months ended March 31, 2023, compared to net comprehensive income of $41.3 million for the three months ended March 31, 2022, primarily as a result of the impact of the fair value of the interest rate cap hedge, partially offset by the increase in net income, as discussed above.

Liquidity and Capital Resources

For the three months ended March 31, 2023 and the twelve months ended December 31, 2022, the Company’s primary sources of liquidity were cash and cash equivalents of $297.8 million and $294.2 million, respectively. As of March 31, 2023, the Company had $219.5 million of borrowings available under its credit facilities (net of $5.5 million undrawn letters of credit issued and outstanding). As of December 31, 2022, the Company had $168.3 million of borrowings available under its credit facilities (net of $6.7 million undrawn letters of credit issued and outstanding). During the three months ended March 31, 2023 and the year ended December 31, 2022, the Company’s positive cash flows from operations enabled investments in pharmacy and information technology infrastructure to support growth and create additional capacity in the future, as well as to pursue acquisitions and share repurchases.

The Company’s primary uses of cash and cash equivalents include supporting our ongoing business activities, investment in capital expenditures in both facilities and technology, the pursuit of acquisitions, and share repurchases. Ongoing operating cash outflows are associated with procuring and dispensing drugs, personnel and other costs associated with servicing patients, as well as paying cash interest on outstanding debt. Ongoing investing cash flows are primarily associated with capital projects related to business acquisitions, the improvement and maintenance of our pharmacy facilities and investment in our information technology systems. Ongoing financing cash flows are primarily associated with the quarterly principal payments on our outstanding debt, along with potential future share repurchases.

Our business strategy includes the deployment of capital to pursue acquisitions that complement our existing operations. We continue to evaluate acquisition opportunities and view acquisitions as a key part of our growth strategy. The Company historically has funded its acquisitions with cash and cash equivalents with the exception of the Merger. The Company may require additional capital in excess of current availability in order to complete future acquisitions. It is impossible to predict the amount of capital that may be required for acquisitions, and there is no assurance that sufficient financing for these activities will be available on acceptable terms.

30

Table of Contents

Short-Term and Long-Term Liquidity Requirements

The Company’s ability to make principal and interest payments on any borrowings under our credit facilities and our ability to fund planned capital expenditures will depend on our ability to generate cash and cash equivalents in the future, which to a certain extent, is subject to general economic, financial, competitive, regulatory and other conditions. Based on our current level of operations and planned capital expenditures, we believe that our existing cash and cash equivalents balances and expected cash flows generated from operations will be sufficient to meet our operating requirements over the next 12 months and beyond. We may require additional borrowings under our credit facilities and alternative forms of financings or investments to achieve our longer-term strategic plans.

Credit Facilities

Effective January 13, 2023, the Company entered into an agreement to amend the ABL Facility, to among other things, increase the amount of borrowing availability by $50.0 million to $225.0 million total borrowing availability and to replace LIBOR with SOFR as the new reference rate. The ABL Facility provides for borrowings up to $225.0 million and matures on October 27, 2026. The ABL Facility bears interest at a rate equal to, at the Company’s election, either (i) a base rate determined in accordance with the ABL Credit Agreement plus an applicable margin, which is equal to between 0.25% and 0.75% based on the historical excess availability as a percentage of the Line Cap (as such term is defined in the ABL Credit Agreement) and (ii) SOFR (or a comparable successor rate, with a floor of 0.00% per annum) plus an applicable margin, which is equal to between 1.25% and 1.75% based on the historical excess availability as a percentage of the Line Cap. The Company had $5.5 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the ABL Facility of $219.5 million as of March 31, 2023.

The principal balance of the First Lien Term Loan is repayable in quarterly installments of $1.5 million plus interest, with a final payment of all remaining outstanding principal due on October 27, 2028. The quarterly principal payments commenced in March 2022. Interest on the First Lien Term Loan is payable monthly on either (i) LIBOR (or a comparable successor rate, with a floor of 0.50% per annum) plus an applicable margin of 2.75% for Eurocurrency Rate Loans and (ii) a base rate determined in accordance with the new First Lien Term Loan agreement, plus 1.75% for Base Rate Loans. The First Lien Term Loan agreement addresses reference rate reform and establishes SOFR as the benchmark replacement when LIBOR ceases to exist.

The Senior Notes bear interest at a rate of 4.375% per annum and are payable semi-annually in arrears on October 31 and April 30 of each year, which began on April 30, 2022. The Senior Notes mature on October 31, 2029.

Interest payments over the course of long-term debt obligations total an estimated $386.5 million based on final maturity dates of the Company’s credit facilities. Interest payments are calculated based on the LIBOR rate as of March 31, 2023. Actual payments are based on changes in LIBOR and exclude the interest rate cap derivative instrument.

31

Table of Contents

Cash Flows

Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022

The following table presents selected data from Option Care Health’s unaudited condensed consolidated statements of cash flows:

	Three Months Ended March 31,
	2023		2022		Variance
	(in thousands)
Net cash provided by operating activities	$	89,752	$	32,681	$	57,071
Net cash used in investing activities	(5,760)		(5,359)		(401)
Net cash used in financing activities	(80,402)		(1,145)		(79,257)
Net increase in cash and cash equivalents	3,590		26,177		(22,587)
Cash and cash equivalents - beginning of period	294,186		119,423		174,763
Cash and cash equivalents - end of period	$	297,776	$	145,600	$	152,176

Cash Flows from Operating Activities

The increase in cash provided by operating activities is primarily due to higher net income, changes in inventory, changes on accounts receivable, prepaid expenses and other current assets, partially offset by certain accruals and timing of vendor payments during the three months ended March 31, 2023 as compared to the three months ended March 31, 2022.

Cash Flows from Investing Activities

The increase in cash used in investing activities during the three months ended March 31, 2023 is primarily due the amount of investments in our pharmacies and infrastructure as compared to the three months ended March 31, 2022.

Cash Flows from Financing Activities

The increase in cash used in financing activities is primarily related to the Company’s repurchase of common stock during the three months ended March 31, 2023, with no comparable activity during the three months ended March 31, 2022.

Critical Accounting Policies and Estimates

The Company prepares its unaudited condensed consolidated financial statements in accordance with GAAP, which requires the Company to make estimates and assumptions. The Company evaluates its estimates and assumptions on an ongoing basis. Estimates and assumptions are based on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making assumptions about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. The Company’s actual results may differ from these estimates, and different assumptions or conditions may yield different estimates.

There have been no material changes to the Company’s critical accounting policies and estimates as presented in our Form 10-K, which are hereby incorporated by reference.

32

Table of Contents

Item 3.Quantitative and Qualitative Disclosures about Market Risk

There have been no material changes to our exposure to market risk from those included in our Form 10-K, which is hereby incorporated by reference.

Item 4.Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures (as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed by the Company in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Under the supervision and with the participation of the Company’s management, including its Chief Executive Officer and Chief Financial Officer, management evaluated the effectiveness of the Company’s disclosure controls and procedures as of March 31, 2023. Based on that evaluation, the Company’s Chief Executive Officer and its Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2023.

Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended March 31, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

33

Table of Contents

PART II

OTHER INFORMATION

Item 1.Legal Proceedings

 For a summary of legal proceedings, refer to Note 13, Commitments and Contingencies, of the unaudited condensed consolidated financial statements included in Item 1 of this Form 10-Q.

Item 1A. Risk Factors

There have been no material changes to the risk factors affecting our business, financial condition or results of operations from those set forth in Part I, Item 1A. “Risk Factors” in our Form 10-K. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition and/or operating results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

On February 20, 2023, the Company’s Board of Directors approved a share repurchase program of up to an aggregate $250.0 million of common stock of the Company.

The following table provides certain information with respect to the Company’s repurchases of common stock from January 1, 2023 through March 31, 2023:

Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
January 1, 2023 - January 31, 2023	—	$	—	—	$	—
February 1, 2023 - February 28, 2023	—	—		—	250,000,000
March 1, 2023 - March 31, 2023	2,475,166	30.30		2,475,166	174,999,995
	2,475,166	$	30.30	2,475,166	$	174,999,995

34

Table of Contents

Item 6.Exhibits

(a) Exhibits.

Exhibit Number	Description
10.1	Fourth Amendment to ABL Credit Agreement, dated as of January 13, 2023 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report 8-K filed on January 19, 2023).
10.2	Share Repurchase Agreement, dated as of February 28, 2023, by and between Option Care Health, Inc. and HC Group Holdings I, LLC (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on March 3, 2023).
10.3	Agreement and Plan of Merger, dated as of May 3, 2023, by and among Option Care Health, Inc., Uintah Merger Sub, Inc., and Amedisys, Inc. (incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K filed on May 3, 2023).
10.4	Commitment Letter, dated as of May 3, 2023, by and between Option Care Health, Inc. and Goldman Sachs Bank USA.
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Labels Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
104	XBRL Formatted Cover Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OPTION CARE HEALTH, INC.
Date: May 4, 2023	/s/ Michael Shapiro
Michael Shapiro
Chief Financial Officer and Senior Vice President (Principal Financial Officer and Duly Authorized Officer)

35

EX-10.4

Execution Version

GOLDMAN SACHS BANK USA

200 West Street

New York, New York 10282

May 3, 2023

Option Care Health, Inc. 3000 Lakeside Dr., #300N Bannockburn, IL 60015 Attention: Mike Shapiro

Project Anderson Senior Credit Facility

Commitment Letter

Ladies and Gentlemen:

You have advised Goldman Sachs Bank USA (together with any of its designated affiliates, “Goldman Sachs” and, together with any other person(s) that become party hereto in accordance with Section 2 below, each a “Commitment Party,” and together, the “CommitmentParties,” “us” or “we”), that you intend to consummate the transactions described in Exhibit A hereto. Capitalized terms used but not defined herein are used with the meanings assigned to them on the exhibits attached hereto (such exhibits, together with this letter, collectively, the “Commitment Letter”).

1.Commitments

In connection with the Transactions, Goldman Sachs (together with any other Initial Senior Lender appointed in accordance with Section 2 below on a several (and not joint) basis, if applicable, each an “Initial Senior Lender,” and collectively, the “Initial Senior Lenders”) is pleased to advise you of its commitment to provide, and hereby agrees to provide, 100% of the principal amount of the Senior Credit Facility (as defined below) upon the terms expressly set forth in this Commitment Letter (including, without limitation, in the Summary of Terms and Conditions attached hereto as Exhibits B (the “Term Sheet”)) and subject solely to the Exclusive Funding Conditions (as defined below). For the avoidance of doubt, the commitments of the Initial Senior Lenders hereunder are several and not joint.

2.Titles and Roles

You hereby appoint (i) Goldman Sachs, together with any other lead arrangers or bookrunners appointed as contemplated in the immediately succeeding paragraph, to act as joint lead arrangers and joint bookrunners (in such capacity, the “Senior Lead Arrangers”) and (ii)

Goldman Sachs to act as sole administrative agent (in such capacity, the “Administrative Agent”) for the Senior Credit Facility.

It is further agreed that Goldman Sachs will have “left” placement on any marketing materials or other documentation used in connection with the Senior Credit Facility and shall hold the leading role and responsibility associated with such “top left” placement. You agree that no other agents or arrangers will be appointed, no other titles will be awarded and no compensation (other than that compensation expressly contemplated by this Commitment Letter and the Fee Letters referred to below) will be paid in connection with obtaining commitments under the Senior Credit Facility unless you and we shall so agree; provided that, on or prior to the date which is fifteen (15) business days after the date you execute and deliver this Commitment Letter, you may appoint additional agents, co-agents, lead arrangers, bookrunners, managers or arrangers (any such agent, co-agent, lead arranger, bookrunner, manager or arranger, an “Additional Agent”) or confer other titles for the Senior Credit Facility in a manner and with economics determined by you (it being understood that to the extent you appoint Additional Agents and/or confer additional titles in respect of the Senior Credit Facility, the economics allocated to, and the commitment amounts of, Goldman Sachs in respect of the Senior Credit Facility will be proportionately reduced by the commitment amount allocated to such Additional Agents (or their affiliates (other than Excluded Affiliates)), in each case upon the execution and delivery by such Additional Agents and you of customary joinder documentation or an amendment to this Commitment Letter and, thereafter, each such Additional Agent shall constitute a “Commitment Party,” “Initial Senior Lender” and/or “Senior Lead Arranger,” as applicable, under this Commitment Letter and under the Fee Letters; provided, that, the aggregate economics payable to Goldman Sachs shall not be less than 10% of the total economics that is otherwise payable to the Commitment Parties in respect to the Senior Credit Facility pursuant to the Fee Letters (exclusive of any fees payable to the Administrative Agent (in its capacity as such)). The parties hereto agree that Excluded Affiliates (as defined below) of such Additional Agents shall be treated in the same manner as Excluded Affiliates of the Initial Senior Lender and Senior Lead Arrangers hereunder. For the avoidance of doubt, your obligations under this paragraph shall automatically terminate upon the date on which this Commitment Letter terminates pursuant to Section 10.

3.Syndication

The Senior Lead Arrangers reserve the right to syndicate the Senior Credit Facility to a group of banks, financial institutions and other institutional lenders, reasonably acceptable to you, such consent not to be unreasonably withheld or delayed (together with the Initial Senior Lenders but excluding Disqualified Institutions, the “Lenders”); provided that, the Senior Lead Arrangers will not syndicate, assign or participate (i) to (a) those persons that are competitors of you, the Company and your or its subsidiaries, to the extent separately identified by you to us (or, after the Closing Date, by the Borrower to the Administrative Agent) in writing from time to time, in each case including any such entity’s affiliates that are identified as such pursuant to this clause (a) or those that are clearly identifiable on the basis of their name (in each case, other than bona fide diversified debt funds) (other than those excluded pursuant to clauses (b) or (c) of this paragraph)), (b) those banks, financial institutions and other persons to the extent separately identified by you to us in writing prior to the date hereof or as you and Goldman Sachs shall mutually agree on or after such date, in each case including any such entity’s affiliates that are

identified as such pursuant to this clause (b) or are clearly identifiable as such on the basis of their name or (c) Excluded Affiliates (such persons or entities in clause (a), (b) or (c), collectively, the “Disqualified Institutions”), provided that any additional designation permitted by the foregoing shall not apply retroactively to any prior allocation, assignment or participation, as applicable. Notwithstanding any other provision of this Commitment Letter to the contrary and notwithstanding any assignment, syndication or participation by the Initial Senior Lenders (except in the case of an assignment to an Additional Agent), (i) subject to your right to appoint Additional Agents in accordance with Section 2 hereof, the Initial Senior Lenders shall not be released, relieved or novated from their respective obligations hereunder (including their respective obligation to fund the Senior Credit Facility on the Closing Date) in connection with any syndication, assignment or participation of the Senior Credit Facility, including their respective commitments in respect thereof, until the initial funding of the Senior Credit Facility on the Closing Date, (ii) subject to your right to appoint Additional Agents in accordance with Section 2 hereof, no assignment or novation shall become effective with respect to all or any portion of the Initial Senior Lenders’ respective commitments in respect of the Senior Credit Facility until the initial funding of the Senior Credit Facility on the Closing Date and (iii) the Initial Senior Lenders shall retain exclusive control over all rights and obligations with respect to their respective commitments in respect of the Senior Credit Facility, including all rights with respect to consents, modifications, supplements and amendments, until the initial funding of the Senior Credit Facility on the Closing Date has occurred.

Notwithstanding anything to the contrary contained in this Commitment Letter or the Fee Letters or any other letter agreement or undertaking concerning the financing of the Transactions to the contrary, neither the commencement nor the completion of the syndication of the Senior Credit Facility, the obtaining of any ratings nor the compliance with any of the other provisions set forth in any provision of this Commitment Letter (other than the Exclusive Funding Conditions (as defined below)) shall constitute a condition to the commitments hereunder or the funding of the Senior Credit Facility on the Closing Date.

The Senior Lead Arrangers, in their capacity as such, will manage, in consultation with you (subject to your rights set forth in the preceding paragraphs of this Section 3 and your rights to appoint Additional Agents in Section 2), all aspects of the syndication, including decisions as to the selection of institutions (other than Disqualified Institutions) to be approached and when they will be approached, when the Lenders’ commitments will be accepted, which Lenders (other than Disqualified Institutions) will participate, the allocation of the commitments among the Lenders and the amount and distribution of fees among the Lenders.

4.Information

You hereby represent and warrant (with respect to Information (as defined below) relating to the Company and its subsidiaries and businesses, to your knowledge) that (a) all written information, other than any projections, forward looking statements and information of a general economic or industry-specific nature, concerning you, the Borrower, the Company and your and their respective subsidiaries, the Merger and the other Transactions contemplated hereby (the “Information”), that has been or will be made available to us by you or your representatives in connection with the transactions contemplated hereby, taken as a whole and as supplemented, does not contain (or, in the case of Information furnished after the date hereof,

will not contain), as of the time it was (or hereafter is) furnished, any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein not materially misleading in light of the circumstances under which such statements are made, as supplemented and updated as provided below and (b) any financial projections that have been or will be made available to us by or on behalf of you in connection with the transactions contemplated hereby have been or will be prepared in good faith based upon assumptions believed by management to be reasonable at the time furnished (it being recognized by the Commitment Parties that (i) such projections are not to be viewed as facts or a guarantee of performance and are subject to significant uncertainties and contingencies many of which are beyond your control and (ii) no assurance can be given that any particular financial projections will be realized, and that actual results during the period or periods covered by any such projections may differ from the projected results, and such differences may be material). You agree that if, at any time prior to the Closing Date, you become aware that any of the representations and warranties in the preceding sentence would be (with respect to Information relating to the Company and its subsidiaries and businesses, to your knowledge) incorrect in any material respect if the Information or projections were being furnished and such representations and warranties were being made at such time, then you will use commercially reasonable efforts to promptly supplement the Information and the projections so that (with respect to Information and projections relating to the Company and its businesses, to your knowledge) such representations are correct, in all material respects, under those circumstances. The making or accuracy of the foregoing representations and warranties, whether or not cured, shall not be a condition to the obligations of the Commitment Parties. You understand that the Commitment Parties may use and rely on the Information and projections without independent verification thereof, and we do not assume responsibility for the accuracy or completeness of the Information or projections, including in the case of the Senior Lead Arrangers, in connection with arranging and syndicating the Senior Credit Facility.

5.Fees

As consideration for the commitments and agreements of the Commitment Parties hereunder, you agree to pay or cause to be paid the nonrefundable compensation and closing payments described in (i) the separate Arranger Fee Letter dated the date hereof among you and us and delivered herewith and (ii) the separate Agent Fee Letter dated the date hereof between you and Goldman Sachs and delivered herewith (each of clauses (i) and (ii) a “Fee Letter” and, collectively, the “Fee Letters”), in each case on the terms and subject to the conditions expressly set forth therein.

6.Conditions

Each Initial Senior Lender’s commitments hereunder are subject solely to the satisfaction (or waiver) of the Exclusive Funding Conditions, and upon the satisfaction (or waiver by the Initial Senior Lenders with respect to the Senior Credit Facility) of the Exclusive Funding Conditions, the initial funding of the Senior Credit Facility shall occur.

Notwithstanding anything in this Commitment Letter, the Fee Letters, the Senior Credit Documentation or any other letter agreement or other undertaking concerning the financing of the transactions contemplated hereby to the contrary, (a) the only representations the accuracy of

which shall be a condition to the availability of the Senior Credit Facility on the Closing Date shall be (i) such of the representations made by or with respect to the Company in the Merger Agreement as are material to the interests of the Lenders, but only to the extent that you or your applicable subsidiaries have the right (determined without regard to any notice provisions but taking into account any applicable cure provisions) to terminate your (or their) obligations under the Merger Agreement or decline to consummate the Merger as a result of a breach of such representations in the Merger Agreement (the “Specified Merger Agreement Representations”) and (ii) the Specified Representations (as defined below) and (b) the terms of the Senior Credit Documentation shall be in a form such that they do not impair the availability of the Senior Credit Facility on the Closing Date if the Exclusive Funding Conditions are satisfied (or waived by the Initial Senior Lenders), it being understood that, to the extent any lien search, insurance certificate or endorsement or Collateral (including the creation or perfection of any security interest) is not or cannot be provided on the Closing Date (other than the pledge and perfection of Collateral of the Borrower and the guarantors party to your existing senior secured revolving and term loan facilities on the Closing Date that are Guarantors of the Senior Credit Facility with respect to which a lien may be perfected solely by the filing of financing statements under the Uniform Commercial Code (“UCC”)), then the provision and/or perfection, as applicable, of any such lien search, insurance certificate or endorsement, and/or Collateral shall not constitute a condition precedent to the availability of the Senior Credit Facility, but may instead be provided within sixty (60) days after the Closing Date, subject to such extensions as are reasonably agreed by the Administrative Agent and the Borrower, or pursuant to arrangements to be mutually agreed by the parties hereto acting reasonably. “Specified Representations” means the representations in the Senior Credit Documentation relating to corporate or other organizational existence, organizational power and authority of the Borrower and the Guarantors (as they relate to due authorization, execution, delivery and performance of the Senior Credit Documentation); due authorization, execution, delivery and enforceability, in each case, relating to the entering into and performance of such Senior Credit Documentation by the Borrower and the Guarantors; solvency as of the Closing Date (after giving effect to the Transactions) of the Borrower and its subsidiaries on a consolidated basis (in form and scope consistent with the solvency certificate to be delivered pursuant to paragraph 1 of Exhibit C hereto); no violations or conflicts with organizational documents (as related to the execution and delivery of the Senior Credit Documentation) of the Borrower and the Guarantors; Federal Reserve margin regulations; the Investment Company Act; the PATRIOT Act; use of proceeds of the Term Loans not violating OFAC or FCPA; and the creation and perfection of the security interests (subject to customary permitted liens) in the Collateral of the Borrower and the Guarantors and subject in all respects to the foregoing provisions of this paragraph. Notwithstanding anything in this Commitment Letter, the Fee Letters, the Senior Credit Documentation or any other letter agreement or other undertaking concerning the financing of the transactions contemplated hereby to the contrary,

(a)the commitments of the Initial Senior Lenders hereunder and the Senior Lead Arrangers’ agreements to perform the services described herein are subject to the conditions set forth in this Section 6 and in Exhibit C hereto (collectively, the “Exclusive Funding Conditions”) and (b) the only conditions (express or implied) to the availability of the Senior Credit Facility on the Closing Date are the Exclusive Funding Conditions. This paragraph, and the provisions herein, shall be referred to as the “Certain Funds Provision.” The Initial Senior Lenders will cooperate with you as reasonably requested in coordinating the timing and procedures for the funding of

the Senior Credit Facility in a manner consistent with the Merger Agreement on the Closing Date.

7.Indemnification and Expenses

You agree (a) to indemnify and hold harmless the Commitment Parties, their controlled affiliates (other than Excluded Affiliates) and controlling persons and the respective directors, officers, employees, agents and other representatives of each of the foregoing and their respective successors (excluding any Excluded Affiliate, each, an “indemnified person”) from and against any and all actual losses, claims, damages, liabilities and expenses, joint or several, to which any such indemnified person may become subject arising out of or in connection with this Commitment Letter, the Fee Letters, the Transactions or the use of proceeds of the Senior Credit Facility or any claim, litigation, investigation or proceeding (a “Proceeding”) relating to any of the foregoing, regardless of whether any indemnified person is a party thereto, whether or not such Proceedings are brought by you, the Company, your or its equity holders, affiliates, creditors or any other person, and to reimburse each indemnified person within thirty (30) days of written demand (together with reasonable backup documentation) for any reasonable out-of- pocket expenses incurred in connection with investigating or defending any of the foregoing (but limited, in the case of legal fees and expenses, to one counsel to such indemnified persons (taken as a whole) and, if reasonably necessary, one local counsel in any relevant material jurisdiction to such indemnified persons (taken as a whole) and, in the case of an actual conflict of interest, one additional counsel to the affected indemnified persons (taken as a whole), in each case excluding allocated costs of in-house counsel); provided that, the foregoing indemnity will not, as to any indemnified person, apply to losses, claims, damages, liabilities or related expenses to the extent they arise from (i) the willful misconduct, bad faith, fraud or gross negligence of such indemnified person (or its controlled affiliates and controlling persons and their respective directors, officers, employees, agents and other representatives (other than Excluded Affiliates)),

(ii) the material breach of the Commitment Letter or Fee Letters by any indemnified person (or its controlled affiliates and controlling persons and their respective directors, officers, employees, agents and other representatives (other than Excluded Affiliates)) (in the case of each of preceding clause (i) and this clause (ii), as determined by a court of competent jurisdiction in a final non-appealable judgment) and (iii) any disputes solely among indemnified persons (other than (x) any claims against the Commitment Parties in their capacity as the Administrative Agent, a Senior Lead Arranger or any similar role under the Senior Credit Facility unless such claim would otherwise be excluded pursuant to clause (i) above and (y) claims arising out of any act or omission of you or the Company) and (b) to reimburse the Commitment Parties and their affiliates (other than any Excluded Affiliate) for all reasonable and documented out-of-pocket expenses (including, but not limited to, due diligence expenses, syndication expenses, travel expenses, and (limited to) reasonable fees, charges and disbursements of one primary counsel to the Senior Lead Arrangers and the Administrative Agent in their capacity as such (which, for the avoidance of doubt, shall not include any fees, charges or disbursements of counsel while acting for any Sale Advisory Person (as defined below))) solely from the date hereof to the Closing Date and, if reasonably necessary, one local counsel in any relevant material jurisdiction incurred in connection with the Senior Credit Facility and any related documentation (including this Commitment Letter, the Fee Letters and the Senior Credit Documentation) or the administration, amendment, modification or waiver of any of the foregoing) within thirty (30) days of written demand (including documentation reasonably supporting such request) (other than with respect

to such fees and expenses paid on the Closing Date for which written demand including documentation reasonably supporting such request is provided at least three (3) business days prior to the Closing Date); provided that, such fees and expenses (i) in the case of legal counsel, shall be limited to the reasonable fees and expenses of counsel described in this clause (b) which, in any event, shall exclude allocated costs of in-house counsel and (ii) in the case of any other advisors and consultants, shall be limited solely to advisors and consultants approved by you. No person a party hereto nor the Company or any indemnified person shall be liable for any damages arising from the use by others of Information or other materials obtained through electronic, telecommunications or other information transmission systems, including, without limitation, SyndTrak, IntraLinks, the internet, email or similar electronic transmission systems, in each case, except to the extent any such damages are found in a final non-appealable judgment of a court of competent jurisdiction to have resulted from the gross negligence, bad faith, fraud or willful misconduct of, or material breach of this Commitment Letter or the Fee Letters by, such person (or its controlled affiliates and controlling persons and their respective directors, officers, employees, agents and other representative (other than Excluded Affiliates)). None of the indemnified persons or you, the Company or any of your or their respective affiliates or the respective directors, officers, employees, advisors, agents and other representatives of the foregoing shall be liable for any indirect, special, punitive or consequential damages in connection with this Commitment Letter, the Fee Letters, the Senior Credit Facility or the transactions contemplated hereby; provided that, nothing contained in this sentence shall limit your indemnification and reimbursement obligations to the extent expressly set forth herein in respect of any losses, claims, damages, liabilities and expenses incurred or paid by an indemnified person to a third party unaffiliated with the Commitment Parties. Each indemnified person (by accepting the benefits hereof) agrees to refund and return any and all amounts paid by you to such indemnified person pursuant to the terms of this paragraph to the extent such indemnified person is not entitled to the payment thereof pursuant to the terms of this paragraph as determined by a court of competent jurisdiction in a final non-appealable judgment.

You shall not be liable for any settlement of any Proceeding (or expenses solely in respect of such settlement) effected without your consent (which consent shall not be unreasonably withheld, delayed or conditioned), but if settled with your written consent, or if there is a final judgment against an indemnified person in any such Proceeding, you agree to indemnify and hold harmless each indemnified person to the extent and in the manner set forth above. You shall not, without the prior written consent of the affected indemnified person (which consent shall not be unreasonably withheld, conditioned or delayed), effect any settlement of any pending or threatened Proceeding against such indemnified person in respect of which indemnity could have been sought hereunder by such indemnified person unless such settlement (a) includes an unconditional release of such indemnified person from all liability or claims that are the subject matter of such Proceeding, (b) includes customary confidentiality provisions and (c) does not include any statement as to any admission of fault, culpability or failure to act by or on behalf of any indemnified person.

In case any Proceeding is instituted involving any indemnified person for which indemnification is to be sought hereunder by such indemnified person, then such indemnified person will promptly notify you of the commencement of any Proceeding after such indemnified person has actual knowledge of the same; provided, however, that the failure so to notify you

will not relieve you from any liability that you may have to such indemnified person pursuant to this Section 7.

Notwithstanding anything to the contrary contained herein, upon the execution of the Senior Credit Documentation (a) the relevant provisions of such definitive documentation shall supersede the provisions of the preceding paragraphs and (b) your obligation pursuant to this Commitment Letter to reimburse an indemnified person (or its related indemnified persons) for losses, claims, damages, liabilities, expenses, fees or any such indemnified obligations or any other expense reimbursement shall automatically terminate and be replaced in all respects by the relevant provisions set forth in the Senior Credit Documentation.

8.Sharing of Information, Absence of Fiduciary Relationship, Affiliate Activities

You acknowledge that the Commitment Parties and their respective affiliates are full service securities firms and we may from time to time (a) effect transactions, for our own or our affiliates’ account or the account of customers, and hold positions in loans, securities or options on loans or securities of you, the Company or its affiliates and of other companies that may be the subject of the transactions contemplated by this Commitment Letter or with which you or the Company may have commercial or other relationships or adverse interests or (b) provide debt financing, equity capital, investment banking, financial advisory services, securities trading, hedging, financing and brokerage activities and financial planning and benefits counseling to other companies in respect of which you may have conflicting interests. In addition, consistent with each Commitment Party’s policy to hold in confidence the affairs of its customers, the Commitment Parties will not furnish information obtained from you, the Company or your or its respective affiliates and representatives to any of their other clients (or to clients of its affiliates) or in connection with the performance by the Senior Lead Arrangers and the Administrative Agent and their respective affiliates of services for its other clients (or for clients of their affiliates). You also acknowledge that the Commitment Parties and their affiliates have no obligation to use in connection with the transactions contemplated hereby, or to furnish to you, confidential information obtained from other companies or other persons.

You further acknowledge and agree that (a) you are capable of evaluating and understanding, and you understand and accept, the terms, risks and conditions of the transactions contemplated by this Commitment Letter, (b) you have been advised that the Commitment Parties and their affiliates are engaged in a broad range of transactions that may involve interests that differ from your and your affiliates’ interests and that the Commitment Parties have no obligation to disclose such interests and transactions to you or your affiliates, (c) you have consulted your own legal, accounting, regulatory and tax advisors to the extent you have deemed appropriate and you are not relying on any Commitment Party for such advice and (d) none of the Commitment Parties nor their affiliates have any obligation to you or your affiliates with respect to the transactions contemplated hereby except those obligations expressly set forth herein or in any other express writing executed and delivered by such Commitment Party and you.

In addition, please note that an affiliate of Goldman Sachs has been retained by you as financial advisors (in such capacity, each a “Financial Advisor”) in connection with the Merger. You agree to such retention, and further agree not to assert any claim you might allege based on

any actual or potential conflicts of interest that might be asserted to arise or result primarily from, on the one hand, the engagement of each Financial Advisor, and on the other hand, our and our affiliates’ relationship with you as described and referred to herein.

Please note that neither the Commitment Parties nor any of their respective affiliates provide tax, accounting or legal advice.

You further acknowledge and agree that (a) no fiduciary, advisory or agency relationship between you and us is intended to be or has been created in respect of any of the transactions contemplated by this Commitment Letter, irrespective of whether we or our affiliates have advised or are advising you on other matters, (b) we, on the one hand, and you, on the other hand, have an arms-length business relationship that does not directly or indirectly give rise to, nor do you rely on, any fiduciary duty on our part, (c) in connection therewith and with the process leading to the Transactions, the Commitment Parties and their respective affiliates (as the case may be) are acting solely as a principal and not as agents or fiduciaries of you and your respective management, stockholders, creditors, affiliates or any other person, (d) you are capable of evaluating and understanding, and you understand and accept, the terms, risks and conditions of the transactions contemplated by this Commitment Letter, (e) you have consulted legal and financial advisors to the extent you deemed appropriate, (f) you have been advised that we and our affiliates are engaged in a broad range of transactions that may involve interests that differ from your interests and that we and our affiliates have no obligation to disclose such interests and transactions to you by virtue of any fiduciary, advisory or agency relationship and

(g) you will not claim that any Commitment Party (in its capacity as such) or its applicable affiliates, as the case may be, have rendered advisory services of any nature or respect, or owe a fiduciary or similar duty to you or your affiliates, in connection with the transactions contemplated by this Commitment Letter or the process leading thereto.

9.Confidentiality

This Commitment Letter is delivered to you on the understanding that neither this Commitment Letter nor the Fee Letters nor any of their terms shall be disclosed to any other person, except (a) to your respective officers, directors, employees, affiliates, members, partners, stockholders, actual and potential co-investors, attorneys, accountants, agents and advisors on a confidential basis, (b) to the Company and its officers, directors, employees, affiliates, members, partners, stockholders, attorneys, accountants, agents and advisors on a confidential basis, (c) in any legal, regulatory, judicial or administrative proceeding or as otherwise required by applicable law, rule or regulation or as requested by a governmental authority (including a self-regulatory authority) (in which case you agree, to the extent permitted by law, rule or regulation, to inform us promptly thereof), (d) in connection with the exercise of any remedy or enforcement of any right under this Commitment Letter and the Fee Letters, (e) the existence and contents of the Commitment Letter and the Term Sheet may be disclosed in any proxy, public filing, prospectus, offering memorandum, offering circulation, syndication materials or other materials in connection with the Transactions, (f) the Term Sheet and Exhibit C hereto (but not the Fee Letters or the contents thereof other than the existence thereof and the contents thereof as part of projections, pro forma information and a generic disclosure of aggregate sources and uses) may be disclosed to actual and prospective Lenders and to any rating agency in connection with the Transactions or in any public regulatory filing requirement relating to the Transactions, (g) to the

extent any such information becomes publicly available other than by reason of disclosure by you, your controlled affiliates or your representatives in violation of this Commitment Letter, (h) with the Commitment Parties’ consent in writing (including via e-mail), and (i) after your acceptance hereof, this Commitment Letter and the Arranger Fee Letter (but not the Agent Fee Letter), including the existence and contents hereof and thereof, may be shared with prospective Additional Agents, in each case on a confidential basis. The foregoing restrictions shall cease to apply after the Senior Credit Documentation shall have been executed and delivered by the parties hereto (other than with respect to any economics referenced in the Fee Letters).

The Commitment Parties shall treat confidentially all information received by them from you, the Company or your or its respective affiliates and representatives in connection with the Merger and the other Transactions and only use such information for the purposes of providing the commitments and, in the case of the Senior Lead Arrangers and the Administrative Agent, the services contemplated by this Commitment Letter; provided, however, that nothing herein shall prevent the Commitment Parties from disclosing any such information (a) to any actual or prospective Lenders, participants or derivative counterparties (other than Disqualified Institutions and persons to whom you have affirmatively denied to provide your consent to the assignment or syndication thereto); provided that, the disclosure of any such information to any actual or prospective Lenders, participants or derivative counterparties shall be made subject to the acknowledgment and acceptance by such actual or prospective Lender, participant or derivative counterparty that such information is being disseminated on a confidential basis (on substantially the terms set forth in this paragraph or as is otherwise reasonably acceptable to you and the Commitment Parties, including, without limitation, as agreed in any confidential information memorandum or other marketing materials) in accordance with the standard syndication or other transfer processes of the Commitment Parties or customary market standards for dissemination of such type of information, in the event of any electronic access through IntraLinks, another website or similar electronic system or platform, which shall in any event require “click through” or other affirmative action on the part of the recipient to access such information and acknowledge its confidentiality obligations in respect thereof, in each case on terms reasonably acceptable to you; (b) in any legal, judicial or administrative proceeding or other compulsory process or otherwise as required by applicable law, rule or regulations or as requested by a governmental authority (in which case such Commitment Party shall promptly notify you, in advance, to the extent permitted by law, rule or regulation (except with respect to any routine audit or examination conducted by bank accountants or regulatory authority exercising routine examination or regulatory authority)); provided that, notwithstanding the foregoing, no notification shall be required in connection with any filings that may be required by the federal securities laws or the rules, regulations, schedules and/or forms of the Securities and Exchange Commission; (c) upon the request or demand of any governmental or regulatory authority having jurisdiction over such Commitment Party or any of its affiliates or upon the good faith determination by counsel that such information should be disclosed in light of ongoing oversight or review of such Commitment Party by any governmental or regulatory authority having jurisdiction over such Commitment Party or its affiliates (in which case such Commitment Party shall, except with respect to any audit or examination conducted by bank accountants or any governmental bank regulatory authority exercising examination or regulatory authority, promptly notify you, in advance, to the extent lawfully permitted to do so); (d) to the lenders, officers, directors, employees, legal counsel, independent auditors, professionals, service providers and other experts or agents of the Commitment Parties (collectively,

“Representatives”) (provided that, any such Representative is advised of its obligation to retain such information as confidential and agrees to keep information of this type confidential and the Commitment Parties shall remain responsible for such Representatives compliance with this provision); (e) to any of its affiliates (other than an Excluded Affiliate) and Representatives of its affiliates (other than an Excluded Affiliate) (provided that, any such affiliate or Representative is advised of its obligation to retain such information as confidential, and the Commitment Parties shall be responsible for the compliance of their affiliates and Representatives of their affiliates with this paragraph) solely in connection with the Senior Credit Facility and the related Transactions; (f) to the extent any such information becomes publicly available other than by reason of disclosure by the Commitment Parties, their affiliates or Representatives in breach of this Commitment Letter or other obligation of confidentiality owed to you, the Company or your or its respective affiliates; (g) for purposes of establishing a “due diligence” defense; (h) to the extent that such information is received by such Commitment Party, its affiliates (other than an Excluded Affiliate) or their respective Representatives from a third party that is not known (after due inquiry) by such Commitment Party to be subject to confidentiality obligations to you, the Company or your or its respective affiliates; (i) to the extent that such information is independently developed by such Commitment Party, its affiliates (other than an Excluded Affiliate) or their respective Representatives without the use of such information; (j) to market data collectors, similar services providers to the lending industry, and service providers to the Senior Lead Arrangers and the Lenders in connection with the administration and management of the Senior Credit Facility; and (k) to enforce their respective rights hereunder or under the Fee Letters; provided, however, that, no such disclosure shall be made by the Commitment Parties to any of their affiliates’ employees, officers, directors, legal counsel, professionals and other experts or agents that are engaged directly or indirectly in a sale of the Company and its subsidiaries as buy-side or sell-side representative and acting in such capacity other than, in each case, any Over the Wall Person (each a “Sale Advisory Person” and an “Excluded Affiliate”) or

(iii) any Disqualified Institution. As used herein, “Over the Wall Person” means, with respect to any Commitment Party, any directors, officers or senior employees of such Commitment Party or any of its affiliates who are required, in accordance with industry regulations, or the applicable Commitment Party’s or its affiliate’s internal policies and procedures to act in a supervisory or managerial capacity and the applicable Commitment Party’s and its affiliates’ internal legal, compliance, risk management, conflicts clearance and other support personnel and credit and investment committee members. The Commitment Parties’ obligations under this paragraph shall remain in effect until the earlier of (x) two years from the date hereof and (y) the date the Senior Credit Documentation (which confidentiality provisions shall include exceptions no less permissive than those contained in this Section) is effective, at which time our obligations under this paragraph shall automatically terminate and be superseded by the confidentiality provisions in the Senior Credit Documentation upon the execution and delivery thereof.

Notwithstanding anything herein to the contrary, any party to this Commitment Letter (and any employee, representative or other agent of such party) may disclose the tax treatment and tax structure of the transactions contemplated by this Commitment Letter and all materials of any kind (including opinions or other tax analyses) that are provided to it relating to such tax treatment and tax structure, except that (i) such disclosures shall not include the identity of any existing or future party (or any affiliate of such party) to this Commitment Letter and (ii) no party shall disclose any information relating to such tax treatment and tax structure to the extent nondisclosure is reasonably necessary in order to comply with applicable securities laws. For this

purpose, the tax treatment of the transactions contemplated by this Commitment Letter shall be any purported or claimed U.S. federal income tax treatment of such transactions and the tax structure of such transactions is any fact that may be relevant to understanding the purported or claimed U.S. federal income tax treatment of such transactions.

10.Miscellaneous

Subject to the immediately following paragraph, this Commitment Letter shall not be assignable by any party hereto (except (i) by us in connection with the appointment of Additional Agents by you as set forth herein and (ii) Goldman Sachs may assign its commitments hereunder to Goldman Sachs Lending Partners LLC (“GSLP”) without the consent of any party hereto, and vice-versa) without the prior written consent of the other parties hereto (and any purported assignment without such consent shall be null and void), is intended to be solely for the benefit of the parties hereto and, to the extent set forth in Section 7, the indemnified persons, and is not intended to and does not confer any benefits upon, or create any rights in favor of, any person other than the parties hereto and the indemnified persons to the extent expressly set forth herein. Each Commitment Party shall be liable solely in respect of its own commitment to the Senior Credit Facility on a several, and not joint, basis with any other Lender. This Commitment Letter may not be amended or waived except by an instrument in writing signed by you and the Commitment Parties. This Commitment Letter may be executed in any number of counterparts, each of which shall be an original, and all of which, when taken together, shall constitute one agreement. Delivery of an executed signature page of this Commitment Letter by facsimile or other electronic transmission (e.g., “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart hereof. The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to this Commitment Letter or any document to be signed in connection hereunder and the transactions contemplated hereby shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other state laws based on the Uniform Electronic Transactions Act, and the parties hereto consent to conduct the transactions contemplated hereunder by electronic means. This Commitment Letter and the Fee Letters are the only agreements that have been entered into among us and you with respect to the Senior Credit Facility and set forth the entire understanding of the parties with respect thereto. This Commitment Letter shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York without regard to principles of conflicts of law, to the extent that the same are not mandatorily applicable by statute and would require or permit the application of the law of another jurisdiction; provided, however, that the laws of the state of Delaware which governs the Merger Agreement shall govern in determining (a) the interpretation of a “Material Adverse Effect” (as defined in the Merger Agreement as in effect on the date hereof) and whether a “Material Adverse Effect” has occurred, (b) the accuracy of any Specified Merger Agreement Representation and whether as a result of any inaccuracy thereof you or your applicable subsidiaries have the right or would have the right (without regard to any notice requirement but taking into account any applicable cure provisions) to terminate your obligations (or to refuse to consummate the Merger) under the Merger Agreement and (c) whether the Merger has been consummated in accordance with the

terms of the Merger Agreement. Each of the parties hereto agrees that (i) this Commitment Letter is a binding and enforceable agreement with respect to the subject matter herein, including an agreement to negotiate in good faith the Senior Credit Documentation by the parties hereto in a manner consistent with this Commitment Letter and the Senior Credit Documentation Principles it being acknowledged and agreed that the funding of the Senior Credit Facility is subject only to the Exclusive Funding Conditions, including the execution and delivery of the Senior Credit Documentation as provided in this Commitment Letter and (ii) the Fee Letters are a binding and enforceable agreement with respect to the subject matter contained therein. Reasonably promptly following the execution of this Commitment Letter, the parties hereto shall proceed with the negotiation in good faith of the Senior Credit Documentation for the purpose of executing and delivering the Senior Credit Documentation substantially simultaneously with the consummation of the Merger. Section headings used herein are for convenience of reference only and are not to affect the construction of, or to be taken into consideration in interpreting, this Commitment Letter.

Each of the parties hereto irrevocably and unconditionally (a) submits, for itself and its property, to the exclusive jurisdiction of any federal court sitting in the Borough of Manhattan in the City of New York or, if that court does not have subject matter jurisdiction, in any state court located in the City and County of New York, and any appellate court from any thereof, over any suit, action or proceeding arising out of or relating to the Transactions or the other transactions contemplated hereby, this Commitment Letter or the Fee Letters or the performance of services hereunder or thereunder or for recognition or enforcement of any judgment and agrees that all claims in respect of any such action or proceeding shall be heard and determined in such New York state or, to the extent permitted by law, in such federal court; provided, however, that the Commitment Parties shall be entitled to assert jurisdiction over you and your property in any court in which jurisdiction may be held over you or your property and (b) agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. You and we agree that service of any process, summons, notice or document by registered mail addressed to any of the parties hereto at the applicable addresses above shall be effective service of process for any suit, action or proceeding brought in any such court. You and we hereby irrevocably and unconditionally waive, to the fullest extent you and we may legally and effectively do so, any objection to the laying of venue of any such suit, action or proceeding brought in any court in accordance with clause (a) of the first sentence of this paragraph and any claim that any such suit, action or proceeding has been brought in any inconvenient forum. YOU AND WE HEREBY IRREVOCABLY WAIVE (TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW) TRIAL BY JURY IN ANY SUIT, ACTION, PROCEEDING, CLAIM OR COUNTERCLAIM BROUGHT BY OR ON BEHALF OF ANY PARTY RELATED TO OR ARISING OUT OF THE TRANSACTIONS, THIS COMMITMENT LETTER OR THE FEE LETTER OR, IN THE CASE OF SENIOR LEAD ARRANGERS AND THE ADMINISTRATIVE AGENT, THE PERFORMANCE OF SERVICES HEREUNDER OR THEREUNDER.

The Commitment Parties hereby notify you that, pursuant to the requirements of the USA PATRIOT Act, Title III of Pub. L. 107-56 (signed into law on October 26, 2001) (as amended, the “PATRIOT Act”), they are required to obtain, verify and record information that identifies the Borrower and each Guarantor, which information includes names, addresses, tax

identification numbers and other information that will allow the Commitment Parties or such Lender to identify the Borrower and each Guarantor in accordance with the PATRIOT Act. This notice is given in accordance with the requirements of the PATRIOT Act and is effective for the Commitment Parties and each Lender.

This paragraph, the indemnification, jurisdiction, waiver of jury trial, service of process, venue, governing law, sharing of information, no agency or fiduciary duty and confidentiality provisions contained herein and in the Fee Letters shall remain in full force and effect regardless of whether definitive financing documentation shall be executed and delivered and notwithstanding the termination of this Commitment Letter or the commitments hereunder; provided that, your obligations under this Commitment Letter (but not the Fee Letters) (and other than your agreements in respect of no fiduciary or similar duties and your obligations in respect confidentiality (which shall terminate in accordance with Section 9)) shall automatically terminate and be superseded by the provisions of the Senior Credit Documentation upon the execution thereof, and you shall automatically be released from all liability in connection therewith at such time. You may terminate the Commitment Parties’ commitments (or a portion thereof) hereunder at any time subject to the provisions of the preceding sentence; provided that in the case of any termination of the commitments under the Senior Credit Facility in part, such termination is applied to reduce the commitments of the Commitment Parties on a pro rata basis.

If the foregoing correctly sets forth our agreement, please indicate your acceptance of the terms of this Commitment Letter and the Fee Letters by returning to us executed counterparts of this Commitment Letter and of the Fee Letters not later than 11:59 p.m., New York time, on May 3, 2023. This offer will automatically expire at such time if we have not received such executed counterparts in accordance with the preceding sentence, unless we shall, in our sole discretion, agree to an extension. Unless we shall, in our sole discretion, agree to an extension, this Commitment Letter and the commitments hereunder shall automatically terminate in the event that (a) in respect of the Senior Credit Facility, if the initial borrowing thereunder does not occur on or before 11:59 p.m., New York City time, on February 5, 2024, as such may be extended pursuant to Section 8.1(b)(i) of the Merger Agreement as in effect on the date hereof (such date, including any such extensions thereof, the “Expiration Time”), (b) the Merger closes with or without the use of the Senior Credit Facility or (c) after execution of the Merger Agreement and prior to the consummation of the Merger, the termination of the Merger Agreement by you or with your written consent (other than with respect to provisions therein that expressly survive termination); provided that, the termination of any commitment pursuant to this sentence does not prejudice your or our rights and remedies in respect of any breach of this Commitment Letter.

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

We are pleased to have been given the opportunity to assist you in connection with this important financing.

Very truly yours,

GOLDMAN SACHS BANK USA

By: /s/ Robert Ehudin

Name: Robert Ehudin

Title: Authorized Signatory

[Project Anderson – Senior Credit Facility Commitment Letter Signature Page]

Accepted and agreed to as of the date first above written:

OPTION CARE HEALTH, INC. (F/K/A BIOSCRIP, INC.),

By:    /s/ Michael Shapiro

Name: Michael Shapiro

Title:    Senior Vice President, Chief Financial Officer and Treasurer

[Senior Credit Facility Commitment Letter Signature Page]

EXHIBIT A

PROJECT ANDERSON

Senior Credit Facility Transaction Summary

Capitalized terms used but not defined in this Exhibit A shall have the meanings set forth in the letter to which this Exhibit A is attached or in Exhibits B or C thereto.

The Borrower intends to consummate a stock-for-stock exchange, directly or indirectly, with a company previously identified to the Commitment Parties as “Apple” (the “Company”), pursuant to the Merger Agreement defined below. In connection therewith, it is intended that:

(a)The Borrower will form Uintah Merger Sub, Inc., a wholly owned subsidiary of the Borrower and a Delaware corporation (“Merger Sub”). On the Closing Date, pursuant to that certain Agreement and Plan of Merger, dated as of the date hereof, by and among the Borrower, Merger Sub, and the Company (together with the exhibits and disclosure schedules thereto, as amended, modified, supplemented or waived, the “Merger Agreement”), Merger Sub shall be merged with and into the Company with the Company as the continuing surviving entity (such merger referred to herein as the “Merger”).

(b)The Borrower will obtain a senior secured 364-day term loan facility in an aggregate principal amount of up to $450 million (the “Senior Credit Facility”), as described in Exhibit B to the Commitment Letter.

(c)All existing indebtedness for borrowed money of the Company and its subsidiaries pursuant to that certain Amended and Restated Credit Agreement, dated as of June 29, 2018, by and among the Company, the lenders from time to time party thereto, the other parties from time to time party thereto and Bank of America, N.A. as administrative agent, will be repaid or satisfied or discharged, and all related guaranties and security interests with respect thereto will be terminated and released substantially concurrently with the initial funding of the Senior Credit Facility (or arrangements for such termination and release shall have been made) (collectively, the “Refinancing”).

(d)The proceeds of the Senior Credit Facility and cash on hand at the Borrower and its subsidiaries (including proceeds available under the ABL Credit Agreement (as defined below)) and the Company and its subsidiaries on the Closing Date will be applied to effect the Refinancing and to pay the fees, closing payments, premiums, expenses and other transaction costs incurred in connection with the Merger and Refinancing (the “Transaction Costs”).

The transactions described above are collectively referred to herein as the “Transactions.” For purposes of the Commitment Letter and the Fee Letters, “Closing Date” shall mean the date of (i) the satisfaction or waiver of the Exclusive Funding Conditions, (ii) the funding of the Senior Credit Facility, (iii) the consummation of the Refinancing and (iv) the consummation of the Merger. The Borrower hereby designates the Transactions described in clauses (a) and (b)

above as a “Limited Condition Transaction” for purposes of (x) the First Lien Credit Agreement,

(y) that certain ABL Credit Agreement, dated as of August 6, 2019 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “ABL CreditAgreement”), by and among Option Care Health, Inc., a Delaware corporation, the other Borrowers (as defined therein) party thereto from time to time, the Guarantors (as defined therein) party thereto from time to time, the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent and (z) that certain Indenture, dated as of October 27, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Indenture”), among the Borrower, as issuer, the guarantors party thereto and Ankura Trust Company, LLC, as trustee, with respect to the Borrower’s 4.375% senior notes due 2029. The indebtedness under the Senior Credit Facility may be incurred under (i) with respect to the First Lien Credit Agreement, Section 7.01(bb), 7.01(gg), 7.03(m) and 7.03(p) thereof, (ii) with respect to the ABL Credit Agreement, Section 7.01(bb), 7.01(gg), 7.03(m) and 7.03(k) thereof, and (iii) with respect to the Indenture, one or more of Sections 3.2(a), 3.2(b)(1), 3.2(b)(5), 3.2(b)(14) and 3.6 thereof and clauses (31) and (33) of the definition of “Permitted Liens”.

EXHIBIT B

PROJECT ANDERSON

Senior Credit Facility Summary of Terms and Conditions

Set forth below is a summary of the principal terms and conditions for the Senior Credit Facility. Capitalized terms used but not defined in this Exhibit B shall have the meanings set forth in the letter to which this Exhibit B is attached or in Exhibits A or C attached thereto.

Borrower:	Option    Care    Health,    Inc.,    a    Delaware    corporation    (the “Borrower”).
Administrative Agent:	Goldman Sachs Bank USA (“Goldman Sachs”) will act as sole and exclusive administrative agent and collateral agent (in such capacity, the “Administrative Agent”) for a syndicate of banks, financial institutions and institutional lenders reasonably acceptable to the Borrower (such consent not to be unreasonably withheld, delayed or conditioned) (excluding any Disqualified Institutions) (the “Lenders”), and will perform the duties customarily associated with such roles.
Senior Lead Arrangers:	Goldman Sachs and each other Senior Lead Arranger appointed pursuant to the Commitment Letter will act as joint lead arrangers for the Senior Credit Facility (together with any additional arranger or bookrunner appointed pursuant to Section 2 of the Commitment Letter in such capacity, the “Senior LeadArrangers”) and as joint lead bookrunners and will perform the duties customarily associated with such roles.
Senior Credit Facility:	A senior secured 364-day term loan facility in an aggregate principal amount equal to $450 million (the “Senior CreditFacility”; the loans thereunder, the “Term Loans”). The Term Loans shall be made in U.S. Dollars.
	The Senior Credit Documentation shall contain customary provisions for replacing or terminating the commitments of any Defaulting Lender (to be defined in the Senior Credit Documentation in a manner consistent with the Senior Credit Documentation Principles).
Incremental Facilities:	None.
Refinancing Facilities:	Substantially the same as the First Lien Credit Agreement.
Purpose:	The proceeds of the Term Loans will be used by the Borrower on the Closing Date, together with certain other available sources of

	funds, to finance a portion of the Refinancing and to pay related fees and expenses (including the payment of Transaction Costs, upfront fees and original issue discount with respect to the Senior Credit Facility).
Availability:	The Term Loans will be available in a single drawing on the Closing Date. Repayments and prepayments of the Term Loans may not be reborrowed.
Interest Rates and Fees:	As set forth on Annex I hereto.
Default Rate:	Any principal payable under or in respect of the Senior Credit Facility not paid when due shall bear interest at the applicable interest rate plus 2% per annum. Other overdue amounts shall bear interest at the interest rate applicable to Base Rate loans plus 2% per annum. Default interest will be payable on demand.
Final Maturity:	The Senior Credit Facility will mature on the date that is three hundred sixty-four (364) days after the Closing Date (the “Maturity Date”).
Amortization:	None.
Guarantees:	Subject to the limitations set forth in the Commitment Letter, including the Certain Funds Provisions, the same guarantees and Guarantors as the First Lien Credit Agreement. “Guarantors” as used in this Commitment Letter has meaning given to such defined term in the First Lien Credit Agreement (it being understood that guarantees by the Company and its subsidiaries shall be provided within sixty (60) days of the Closing Date).

Security:

Subject to the Certain Funds Provision, the same as the First Lien Credit Agreement. “Collateral” as used in this Commitment Letter has the same meaning given to such term in the First Lien Credit Agreement. The Senior Credit Facility shall be secured by the Collateral on a pari passu basis with the liens on the Collateral securing the Term Loans (as defined in the First Lien Credit Agreement), pursuant to the Pari Passu Intercreditor Agreement (as defined below).

Mandatory Prepayments and Commitment Reductions:

Subject to the Intercreditor Agreements, limited to the mandatory prepayments set forth in Section 2.05(b)(ii), Section 2.05(b)(iii) and Section 2.05(b)(iv) of the First Lien Credit Agreement (and subject to the ratable reduction provisions in Section 2.05(b)(vi) of the First Lien Credit Agreement for proceeds applied to “Other Applicable Indebtedness”). In addition, (i) the commitments under the Senior Credit Facility shall be automatically reduced, on a dollar-for-dollar basis, by the amount of net cash proceeds received by the Borrower and its subsidiaries from any Permanent Financing consummated on or prior to the Closing Date and (ii) the Term Loans outstanding shall be repaid, on a dollar-for-dollar basis, by the amount of net cash proceeds received by the Borrower and its subsidiaries from any Permanent Financing consummated after the Closing Date. “Permanent Financing” means any debt or equity financing (whether in the form of loans, securities or otherwise), (a) prior to the Closing Date, that is incurred to refinance or replace the Senior Credit Facility, and (b) in excess of, individually or in the aggregate, $500,000,000 that is incurred following the Closing Date, subject in the case of this clause (b) to exceptions for (i) revolving loans borrowed under the ABL Credit Agreement, (ii) financing incurred by the Borrower and its subsidiaries in the ordinary course of business consistent with past practice, (iii) refinancings of existing outstanding indebtedness of the Borrower and its subsidiaries (excluding, for the avoidance of doubt, refinancing the indebtedness of the Company contemplated hereunder), and (iv) other working capital facilities.

Voluntary Prepayments and Reductions in Commitments:	Substantially the same as the First Lien Credit Agreement.
Call Protection:	None.
Senor Credit Documentation:	The definitive documentation for the Senior Credit Facility (the “Senior Credit Documentation”) shall be initially drafted by counsel to the Borrower, shall be substantially consistent with (and except as set forth herein, no less favorable to the Borrower and its subsidiaries than) that certain Amended and Restated First Lien Credit Agreement, dated as of October 27, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof and adjusted pursuant to the terms below, the “First Lien CreditAgreement”), by and among Option Care Health, Inc, a Delaware corporation, the other Borrowers (as defined therein) party thereto from time to time, the Guarantors (as defined therein) party thereto from time to time, the Lenders (as defined therein) from time to time party thereto, and Bank of America, N.A., as administrative agent (as amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, and adjusted pursuant to terms below, the “SeniorCredit Documentation Principles”) and take into account (a) the terms set forth in this Commitment Letter, (b) changes in law or accounting standards or to cure mistakes or defects, (c) modifications reasonably acceptable to the Borrower and Goldman Sachs to prevent the release of any Guarantor from its obligations under the Senior Credit Documentation solely as a result of such Guarantor becoming a “non-wholly owned subsidiary” unless such transaction is a result of a joint venture or other strategic transaction entered into for a bona fide business purpose, (d) modifications reasonably acceptable to the Borrower and Goldman Sachs to make amendments to the Senior Credit Documentation (i) to permit any payment or lien subordination or (ii) to modify pro rata payment sharing provisions shall, in each case, be subject to an “affected lender” vote, and (e) any changes in the operational and agency requirements of the Administrative Agent (including Term SOFR-related provisions customary for similar financings as to which the Administrative Agent acts as administrative agent) and in any event will contain only those conditions to borrowing, mandatory prepayments, representations, warranties, affirmative, negative and financial covenants and events of default expressly set forth in this Term Sheet, in each case applicable to the Borrower and its restricted subsidiaries. The definitive terms will be negotiated in good faith to finalize the Senior Credit Documentation, giving effect to the Certain Funds Provision and the Senior Credit Documentation Principles, as promptly as reasonably practicable.

Intercreditor Agreements:	Administrative Agent shall (a) join as a party to the ABL Intercreditor Agreement (as defined in the First Lien Credit Agreement) (the “ABL Intercreditor Agreement”), as agent and representative of the Lenders under the Senior Credit Facility, and (b) enter into a pari passu intercreditor agreement with the administrative agent under the First Lien Credit Agreement in the form attached as Exhibit J to the First Lien Credit Agreement (the “Pari Passu Intercreditor Agreement” and, together with the ABL Intercreditor Agreement, collectively, the “IntercreditorAgreements”).
Representations and Warranties:	Subject in all    respects to the Certain Funds Provision, substantially the same as the First Lien Credit Agreement.
Conditions Precedent to Initial Borrowings:	Subject to the Certain Funds Provision, the availability of the Senior Credit Facility on the Closing Date will be subject only to the Exclusive Funding Conditions.
Conditions Precedent to Ongoing Borrowings:	N/A

Affirmative Covenants:	Subject to the Certain Funds Provision, substantially the same as the First Lien Credit Agreement.
Negative Covenants:	Substantially the same as the First Lien Credit Agreement; provided, that the debt, liens and restricted payments provisions shall be more restrictive on the Borrower and its restricted subsidiaries in a manner to be agreed.
Financial Covenant:	None.
Unrestricted Subsidiaries:	Substantially the same as the First Lien Credit Agreement.
Events of Default:	Substantially the same as the First Lien Credit Agreement.
Voting:	Substantially the same as the First Lien Credit Agreement.
Cost and Yield Protection:	Substantially the same as the First Lien Credit Agreement.
Assignments and Participations:	Substantially the same as the First Lien Credit Agreement; provided that Goldman Sachs shall be permitted to assign its commitments and Term Loans to GSLP (and vice-versa) without any required consents.
Expenses and Indemnification:	Substantially the same as the First Lien Credit Agreement.

Governing Law and Forum:

New York; provided, however, that the laws of the state of Delaware which governs the Merger Agreement shall govern in determining (a) the interpretation of a “Material Adverse Effect” (as defined in the Merger Agreement as in effect on the date hereof) and whether a “Material Adverse Effect” has occurred, (b) the accuracy of any Specified Merger Agreement Representation and whether as a result of any inaccuracy thereof you or your applicable subsidiaries have the right or would have the right (without regard to any notice requirement but taking into account any applicable cure provisions) to terminate your obligations (or to refuse to consummate the Merger) under the Merger Agreement and (c) whether the Merger has been consummated in accordance with the terms of the Merger Agreement.

Counsel to the Administrative Agent and Commitment Parties:

Davis Polk & Wardwell LLP.

Annex I to Exhibit BInterest Rates:    The interest rates under the Senior Credit Facility will be as follows:

At the option of the Borrower, (x) Term SOFR plus the Term SOFR Applicable Margin or (y) Base Rate plus the Base Rate Applicable Margin.

Time Period	Term    SOFR Applicable Margin	Base    Rate Applicable Margin
Closing Date to the date that is 89 days after the Closing Date	2.00%	1.00%
90 days after the Closing Date to the date that is 179 days after the Closing Date	2.50%	1.50%
180 days after the Closing Date to the date that is 269 days after the Closing Date	3.00%	2.00%
270 days after the Closing Date and thereafter	3.50%	2.50%

The Borrower may elect interest periods of 1, 3 or 6 months for Term SOFR borrowings.

Calculation of interest shall be on the basis of the actual days elapsed in a year of 360 days (or 365 or 366 days, as the case may be, in the case of Base Rate loans based on the Prime Rate) and interest shall be payable

(i) in the case of Term SOFR loans, at the end of each interest period and, in any event, at least every 3 months and (ii) in the case of Base Rate loans, quarterly in arrears.

“Base Rate” means for any day a fluctuating rate per annum equal to the highest of (a) the Federal Funds Rate plus 0.50%, (b) the rate of interest in effect for such day as publicly announced from time to time by the Administrative Agent as its “prime rate” and (c) Term SOFR for an interest period of one month plus 1.00% (or, if such day is not a business day, the immediately preceding business day).

“SOFR” means, with respect to any business day, a rate per annum equal to the secured overnight financing rate for such business day

published by the SOFR Administrator on the SOFR Administrator’s Website at approximately 8:00 a.m. (New York City time). “SOFR Administrator” means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate). “SOFR Loan” means a loan bearing interested determined by reference to Term SOFR. “Term SOFR” shall mean, with respect to any SOFR Loan denominated in U.S. Dollars and for any interest period, the Term SOFR Reference Rate for a tenor comparable to the applicable interest period on the day (such day, the “Periodic Term SOFR Determination Day”) that is two (2) business days prior to the first day of such interest period, as such rate is published by the Term SOFR Administrator; provided, however, that if as of 5:00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor published by the Term SOFR Administrator on the business day first preceding such Periodic Term SOFR Determination Day so long as such business day is not more than three (3) business days prior to such Periodic Term SOFR Determination Day. “Term SOFR Administrator” shall mean CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Administrative Agent in its reasonable discretion). “Term SOFR Reference Rate” shall mean, for any day and time, with respect to any SOFR Loan for any interest period, the rate per annum determined by the Administrative Agent as the forward-looking term rate based on SOFR. Term SOFR shall be subject to a floor of 0.00%

Duration Fees:

The Borrower will pay a fee (the “Duration Fee”), for the ratable benefit of the Lenders, in an amount equal to (i) 0.75% of the aggregate principal amount of the Term Loans under the Senior Credit Facility outstanding on the date which is 90 days after the Closing Date, due and payable in cash on such 90th day (or if such day is not a business day, the next business day); (ii) 1.00% of the aggregate principal amount of the Term Loans under the Senior Credit Facility outstanding on the date which is 180 days after the Closing Date, due and payable in cash on such 180th day (or if such day is not a business day, the next business day); and (iii) 1.25% of the aggregate principal amount of the Term Loans under the Senior Credit Facility outstanding on the date which is 270 days after the Closing Date, due and payable in cash on such 270th day (or if such day is not a business day, the next business day).

EXHIBIT C

PROJECT ANDERSON

Conditions

The availability of the Senior Credit Facility shall be subject solely to the satisfaction or waiver by the Initial Senior Lenders with commitments in respect of the Senior Credit Facility of the following conditions (subject to the Certain Funds Provision). Capitalized terms used but not defined in this Exhibit C have the meanings set forth in the letter to which this Exhibit C is attached or in Exhibits A or B thereto.

1.Subject to the Certain Funds Provision, the Borrower and each Guarantor shall have executed and delivered the Senior Credit Documentation, in each case, consistent with the Commitment Letter and Term Sheet, to which they are parties and the Commitment Parties shall have received:

(a)a customary notice of borrowing;

(b)customary closing officer’s certificate (certifying as to resolutions, organizational documents and incumbency, as to the accuracy of the Specified Representations in all material respects and no amendments or modifications to the provisions of the Merger Agreement that are materially adverse to the interests of the Initial Senior Lenders) and good standing (of the jurisdiction of organization of the Borrower and Guarantors) and legal opinions; and

(c)a certificate (substantially in the form of Annex I to this Exhibit C) from the chief financial officer (or other officer with reasonably equivalent duties) of the Borrower certifying that the Borrower and its subsidiaries, on a consolidated basis after giving effect to the Transactions, are solvent.

2.Prior to, or substantially concurrently with the initial fundings contemplated by the Commitment Letter, the Refinancing shall have been consummated.

3.The Merger shall be consummated in all material respects pursuant to the Merger Agreement (for the avoidance of doubt, the Initial Senior Lenders are satisfied with the Merger Agreement dated the date hereof) substantially concurrently with the initial funding of the Senior Credit Facility without giving effect to any amendments or modifications to the provisions thereof or express waivers or consents thereto that, in each case, are materially adverse to the interests of the Initial Senior Lenders without the consent of the Initial Senior Lenders, such consent not to be unreasonably withheld, conditioned or delayed (it being understood and agreed that (i) any change in the Merger Consideration (as defined in the Merger Agreement) shall be deemed not to be adverse to the interest of the Initial Senior Lenders and (ii) any adverse modification to the definition of Material Adverse Effect (as defined in the Merger Agreement as in effect on the date hereof) (or adverse express waiver or express consent in respect of the definition of Material Adverse Effect) without the prior written consent of the Initial Senior Lenders (such consent not to be unreasonably withheld, delayed or conditioned) shall be deemed to be materially adverse to the interests of the Initial Senior Lenders); provided that in each case the Initial Senior Lenders shall be deemed to have consented to such modification, amendment,

waiver or consent unless they shall object thereto within 3 business days of receipt of written notice of such modification, amendment, consent or waiver.

4.Since December 31, 2022, there have been no Changes (as defined in the Merger Agreement as in effect on the date hereof) that, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect on Apple (each as defined in the Merger Agreement as in effect on the date hereof).

5.So long as requested at least ten (10) business days prior to the Closing Date, the Administrative Agent shall have received, at least three (3) business days prior to the Closing Date, all documentation and other information with respect to the Borrower and the Guarantors that is required by regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including, without limitation, the PATRIOT Act.

6.Payment of all fees and expenses earned, due and payable to the Commitment Parties and the Lenders required to be paid on the Closing Date under the Senior Credit Facility for which invoices have been received at least three (3) business days in advance (which amounts may be offset against the proceeds of the Senior Credit Facility) shall have been made (or shall be made substantially contemporaneously with funding).

7.Subject to the Certain Funds Provision, with respect to the Senior Credit Facility, all actions necessary to establish that the Administrative Agent will have a perfected security interest in the Collateral of the Borrower and each Guarantor under the Senior Credit Facility shall have been taken (or shall be taken substantially contemporaneously with funding).

8.The Specified Merger Agreement Representations and the Specified Representations shall be true and correct in all material respects.

9.Not less than 14 calendar days prior to the Closing Date, one or more investment banks reasonably satisfactory to the Senior Lead Arrangers shall have been engaged to arrange, underwrite or otherwise place the Permanent Financing.

FORM OF SOLVENCY CERTIFICATE

Annex I to Exhibit C

[●],

This Solvency Certificate is being executed and delivered pursuant to Section [●]of that certain [●]1 (the “Credit Agreement”); the terms defined therein being used herein as therein defined.

I, [●], the [chief financial officer/equivalent officer] of the Borrower, solely in such capacity and not in an individual capacity, hereby certify that I am the [chief financial officer/equivalent officer] of the Borrower and that I am generally familiar with the businesses and assets of the Borrower and its Subsidiaries (taken as a whole), I have made such other investigations and inquiries as I have deemed appropriate and I am duly authorized to execute this Solvency Certificate on behalf of the Borrower pursuant to the Credit Agreement.

I further certify, solely in my capacity as [chief financial officer/equivalent officer] of the Borrower, and not in my individual capacity, as of the date hereof and after giving effect to the Transactions and the incurrence of the indebtedness and obligations being incurred in connection with the Credit Agreement and the Transactions on the date hereof, that, (a) the sum of the debt (including contingent liabilities) of the Borrower and its Subsidiaries, taken as a whole, does not exceed the present fair saleable value (on a going concern basis) of the assets of the Borrower and its Subsidiaries, taken as a whole; (b) the capital of the Borrower and its Subsidiaries, taken as a whole, is not unreasonably small in relation to the business of the Borrower and its Subsidiaries, taken as a whole, contemplated as of the date hereof; and (c) the Borrower and its Subsidiaries, taken as a whole, do not intend to incur, or believe that they will incur, debts including current obligations beyond their ability to pay such debt as they mature in the ordinary course of business. For the purposes hereof, the amount of any contingent liability at any time shall be computed as the amount that, in light of all of the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability (irrespective of whether such contingent liabilities meet the criteria for accrual under Statement of Financial Accounting Standard No. 5).

[Remainder of page intentionally left blank]

1    Describe Credit Agreement.

IN WITNESS WHEREOF, I have executed this Solvency Certificate on the date first written above.

By:    

Name: [●]

Title:    [●]

EX-31.1

EXHIBIT 31.1 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John Rademacher, certify that:

1.     I have reviewed this Quarterly Report on Form 10-Q of Option Care Health, Inc.;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 4, 2023

/s/ John Rademacher

John Rademacher

President, Chief Executive Officer and Principal Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael Shapiro, certify that:

1.     I have reviewed this Quarterly Report on Form 10-Q of Option Care Health, Inc.;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 4, 2023

/s/ Michael Shapiro

Michael Shapiro

Chief Financial Officer and Principal Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

    In connection with the Quarterly Report of Option Care Health, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Rademacher, Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 4, 2023

/s/ John Rademacher

John Rademacher

President, Chief Executive Officer and Principal Executive Officer

EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

    In connection with the Quarterly Report of Option Care Health, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael Shapiro, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 4, 2023

/s/ Michael Shapiro

Michael Shapiro

Chief Financial Officer and Principal Financial Officer

XML

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	May 02, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-11993
Entity Registrant Name	OPTION CARE HEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	05-0489664
Entity Address, Address Line One	3000 Lakeside Dr.
Entity Address, Address Line Two	Suite 300N,
Entity Address, City or Town	Bannockburn,
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60015
City Area Code	312
Local Phone Number	940-2443
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	OPCH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		179,764,281
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 297,776	$ 294,186
Accounts receivable, net	395,209	377,542
Inventories	249,643	224,281
Prepaid expenses and other current assets	86,908	98,330
Total current assets	1,029,536	994,339
NONCURRENT ASSETS:
Property and equipment, net	105,571	108,321
Operating lease right-of-use asset	70,077	72,424
Intangible assets, net	21,677	22,371
Referral sources, net	334,001	341,744
Goodwill	1,533,569	1,533,424
Other noncurrent assets	35,971	40,313
Total noncurrent assets	2,100,866	2,118,597
TOTAL ASSETS	3,130,402	3,112,936
CURRENT LIABILITIES:
Accounts payable	448,890	378,763
Accrued compensation and employee benefits	48,550	76,906
Accrued expenses and other current liabilities	96,279	84,302
Current portion of operating lease liability	18,847	19,380
Current portion of long-term debt	6,000	6,000
Total current liabilities	618,566	565,351
NONCURRENT LIABILITIES:
Long-term debt, net of discount, deferred financing costs and current portion	1,057,787	1,058,204
Operating lease liability, net of current portion	69,961	71,441
Deferred income taxes	30,780	22,154
Other noncurrent liabilities	3,089	9,683
Total noncurrent liabilities	1,161,617	1,161,482
Total liabilities	1,780,183	1,726,833
STOCKHOLDERS’ EQUITY:
Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of March 31, 2023 and December 31, 2022, respectively	0	0
Common stock; $0.0001 par value: 250,000,000 shares authorized, 182,615,601 shares issued and 179,756,714 shares outstanding as of March 31, 2023; 182,341,420 shares issued and 181,957,698 shares outstanding as of December 31, 2022	18	18
Treasury stock; 2,858,887 and 383,722 shares outstanding, at cost, as of March 31, 2023 and December 31, 2022, respectively	(78,138)	(2,403)
Paid-in capital	1,180,992	1,176,906
Retained earnings	229,631	190,423
Accumulated other comprehensive income	17,716	21,159
Total stockholders’ equity	1,350,219	1,386,103
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 3,130,402	$ 3,112,936

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	12,500,000	12,500,000
Preferred stock, shares, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares, issued (in shares)	182,615,601	182,341,420
Common stock, shares, outstanding (in shares)	179,756,714	181,957,698
Treasury stock, at cost (in shares)	2,858,887	383,722

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
NET REVENUE	$ 1,015,848	$ 915,784
COST OF REVENUE	786,843	714,848
GROSS PROFIT	229,005	200,936
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses	147,866	133,969
Depreciation and amortization expense	14,514	14,722
Total operating expenses	162,380	148,691
OPERATING INCOME	66,625	52,245
OTHER INCOME (EXPENSE):
Interest expense, net	(13,834)	(12,246)
Equity in earnings of joint ventures	1,437	1,267
Other, net	1	2
Total other expense	(12,396)	(10,977)
INCOME BEFORE INCOME TAXES	54,229	41,268
INCOME TAX EXPENSE	15,021	10,993
NET INCOME	39,208	30,275
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $1,152 and ($3,763), respectively	(3,443)	11,070
OTHER COMPREHENSIVE (LOSS) INCOME	(3,443)	11,070
NET COMPREHENSIVE INCOME	$ 35,765	$ 41,345
EARNINGS PER COMMON SHARE:
Earnings per share, basic (in dollars per share)	$ 0.22	$ 0.17
Earnings per share, diluted (in dollars per share)	$ 0.21	$ 0.17
Weighted average common shares outstanding, basic (in shares)	181,262	179,961
Weighted average common shares outstanding, diluted (in shares)	182,735	181,681

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Unrealized gains (losses) on cash flow hedges, net of income tax expense	$ 1,152	$ 3,763

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 39,208	$ 30,275
Adjustments to reconcile net income to net cash provided by operations:
Depreciation and amortization expense	15,225	15,979
Non-cash operating lease costs	5,540	3,884
Deferred income taxes - net	8,626	12,996
Amortization of deferred financing costs	1,083	1,049
Equity in earnings of joint ventures	(1,437)	(1,267)
Stock-based incentive compensation expense	5,988	4,178
Proceeds from Equity Method Investment, Distribution	2,500	0
Other adjustments	198	291
Changes in operating assets and liabilities:
Accounts receivable, net	(17,812)	(28,766)
Inventories	(25,362)	(34,089)
Prepaid expenses and other current assets	9,977	(6,241)
Accounts payable	70,127	76,872
Accrued compensation and employee benefits	(28,356)	(41,481)
Accrued expenses and other current liabilities	14,831	13,520
Operating lease liabilities	(5,271)	(4,246)
Other noncurrent assets and liabilities	(5,313)	(10,273)
Net cash provided by operating activities	89,752	32,681
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment	(5,760)	(5,359)
Net cash used in investing activities	(5,760)	(5,359)
CASH FLOWS FROM FINANCING ACTIVITIES:
Exercise of stock options, vesting of restricted stock, and related tax withholdings	(1,902)	355
Repayments of debt principal	(1,500)	(1,500)
Purchase of company stock	(75,000)	0
Other financing activities	(2,000)	0
Net cash used in financing activities	(80,402)	(1,145)
NET INCREASE IN CASH AND CASH EQUIVALENTS	3,590	26,177
Cash and cash equivalents - beginning of the period	294,186	119,423
CASH AND CASH EQUIVALENTS - END OF PERIOD	297,776	145,600
Supplemental disclosure of cash flow information:
Cash paid for interest	11,161	5,104
Cash paid for income taxes	0	61
Cash paid for operating leases	$ 6,527	$ 6,242

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Treasury Stock	Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income
Equity, beginning balance at Dec. 31, 2021	$ 1,175,886	$ 0	$ 18	$ (2,403)	$ 1,138,855	$ 39,867	$ (451)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options, vesting of restricted stock, and related tax withholdings	355				355
Stock-based incentive compensation	4,178				4,178
Net income	30,275					30,275
Other comprehensive income	11,070						11,070
Equity, ending balance at Mar. 31, 2022	1,221,764	0	18	(2,403)	1,143,388	70,142	10,619
Equity, beginning balance at Dec. 31, 2022	1,386,103	0	18	(2,403)	1,176,906	190,423	21,159
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options, vesting of restricted stock, and related tax withholdings	(1,902)				(1,902)
Stock-based incentive compensation	5,988				5,988
Purchase of company stock	(75,735)			(75,735)
Net income	39,208					39,208
Other comprehensive income	(3,443)						(3,443)
Equity, ending balance at Mar. 31, 2023	$ 1,350,219	$ 0	$ 18	$ (78,138)	$ 1,180,992	$ 229,631	$ 17,716

XML

NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS

NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS

Corporate Organization and Business — HC Group Holdings II, Inc. (“HC II”) was incorporated under the laws of the State of Delaware on January 7, 2015, with its sole shareholder being HC Group Holdings I, LLC. (“HC I”). On April 7, 2015, HC I and HC II collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care, Inc. (“Option Care”).

On March 14, 2019, HC I and HC II entered into a definitive agreement (the “Merger Agreement”) to merge with and into a wholly-owned subsidiary of BioScrip, Inc. (“BioScrip”) (the “Merger”), a national provider of infusion and home care management solutions, which was completed on August 6, 2019 (the “Merger Date”). Following the close of the transaction, BioScrip was rebranded as Option Care Health. The combined Company’s stock is listed on the Nasdaq Global Select Market as of March 31, 2023. During the three months ended March 31, 2023, HC I completed a secondary offering of 13,000,000 shares of common stock. In addition to this secondary offering, the Company repurchased 2,475,166 shares from HC I on March 3, 2023 under the Company’s share repurchase program. See Note 15, Stockholders’ Equity, for further discussion of the Company’s share repurchase program. Following these transactions, HC I holds approximately 6% of the common stock of the Company.

Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 95 full service pharmacies and 73 stand-alone ambulatory infusion suites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services.

Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2022 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.

Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.

The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the unaudited condensed consolidated statements of comprehensive income. See Equity-Method Investments within Note 2, Summary of Significant Accounting Policies, for further discussion of the Company’s equity-method investments.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March 31, 2023, cash equivalents consisted of money market funds.

Prepaid Expenses and Other Current Assets — Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $48.3 million and $53.4 million as of March 31, 2023 and December 31, 2022, respectively.

Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March 31, 2023 and December 31, 2022, the balance of the investments was $18.3 million and $19.4 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.4 million and $1.3 million for the three months ended March 31, 2023 and 2022, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March 31, 2023, the Company received a distribution of $2.5 million from the investees. During the three months ended March 31, 2022, the Company did not receive a distribution from the investees. See Note 16, Related-Party Transactions, for discussion of related-party transactions with these investees.

Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 14% and 15% for the three months ended March 31, 2023 and 2022, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.

For the three months ended March 31, 2023 and 2022, approximately 12% and 13%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. As of March 31, 2023 and December 31, 2022, approximately 11% and 13%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.

The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.

For the three months ended March 31, 2023 and 2022, approximately 72% and 75%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results. Although there remains some uncertainty regarding the COVID-19 pandemic, as of March 31, 2023, the Company has been able to maintain adequate levels of supplies and pharmaceuticals to support its operations.

XML

BUSINESS COMBINATIONS

3 Months Ended

Mar. 31, 2023

Business Combination and Asset Acquisition [Abstract]

BUSINESS COMBINATIONS

BUSINESS COMBINATIONS

Rochester Home Infusion, Inc. — In August 2022, pursuant to the stock purchase agreement dated June 10, 2022, the Company completed the acquisition of 100% of the equity interests in Rochester Home Infusion, Inc. (“RHI”) for a purchase price, net of cash acquired, of $27.4 million.

The allocation of the purchase price of RHI was accounted for as a business combination in accordance with ASC Topic 805, Business Combinations, with the total purchase price being allocated to the assets and liabilities acquired based on the relative fair value of each asset and liability. The following is a final allocation of the consideration transferred to acquired identifiable assets and assumed liabilities, net of cash acquired, as of March 31, 2023 (in thousands):

	Amount
Accounts receivable	$	686
Intangible assets	5,449
Other assets	394
Accounts payable and other liabilities	(434)
Fair value identifiable assets and liabilities	6,095
Goodwill (1)	21,323
Cash acquired	201
Purchase price	27,619
Less: cash acquired	(201)
Purchase price, net of cash acquired	$	27,418

(1) Goodwill is attributable to cost synergies from procurement and operational efficiencies and elimination of duplicative administrative costs.

XML

REVENUE

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

REVENUE

REVENUE

The following table sets forth the net revenue earned by category of payer for the three months ended March 31, 2023 and 2022 (in thousands):

	Three Months Ended March 31,
	2023		2022
Commercial payers	$	873,911	$	786,278
Government payers	122,789		115,205
Patients	19,148		14,301
Net revenue	$	1,015,848	$	915,784

XML

INCOME TAXES

3 Months Ended

Mar. 31, 2023

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

During the three months ended March 31, 2023 and 2022, the Company recorded tax expense of $15.0 million and $11.0 million, respectively, which represents an effective tax rate of 27.7% and 26.6%, respectively. The variance in the Company’s effective tax rate of 27.7% for the three months ended March 31, 2023, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, as well as various non-deductible expenses. The variance in the Company’s effective tax rate of 26.6% for the three months ended March 31, 2022, compared to the federal statutory rate of 21%, is primarily attributable to current and deferred state taxes as well as various non-deductible expenses.

The Company maintains a valuation allowance of $13.1 million against certain state net operating losses. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. In making this assessment, the Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income, and tax-planning strategies. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.

The Company’s tax expense for the three months ended March 31, 2023 of $15.0 million consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense. The Company’s tax expense for the three months ended March 31, 2022 of $11.0 million consists of quarterly tax liabilities attributed to specific state taxing authorities as well as recognized deferred federal and state tax expense.

The Company has accumulated federal net operating loss carryovers that are subject to one or more Section 382 limitations. This may limit the Company’s ability to utilize its federal net operating losses

XML

EARNINGS PER SHARE

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

EARNINGS PER SHARE

EARNINGS PER SHARE

The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.

The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three months ended March 31, 2023 and 2022 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods. As of March 31, 2023, there were 871,491 stock option awards, 342,894 restricted stock awards and 90,159 performance stock unit awards outstanding that were excluded from the calculation of earnings per share as they would be anti-dilutive. As of March 31, 2022, there were 457,752 warrants, 770,303 stock option awards, and 269,670 restricted stock awards outstanding that were excluded from the calculation of earnings per share as they would be anti-dilutive.

The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):

	Three Months Ended March 31,
	2023		2022
Numerator:
Net income	$	39,208	$	30,275
Denominator:
Weighted average number of common shares outstanding	181,262		179,961
Earnings per common share:
Earnings per common share, basic	$	0.22	$	0.17

The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):

	Three Months Ended March 31,
	2023		2022
Numerator:
Net income	$	39,208	$	30,275
Denominator:
Weighted average number of common shares outstanding	181,262		179,961
Effect of dilutive securities	1,473		1,720
Weighted average number of common shares outstanding, diluted	182,735		181,681
Earnings per common share:
Earnings per common share, diluted	$	0.21	$	0.17

XML

LEASES

3 Months Ended

Mar. 31, 2023

Leases [Abstract]

LEASES

LEASES

During the three months ended March 31, 2023 and 2022, the Company incurred operating lease expenses of $7.0 million and $7.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March 31, 2023, the weighted-average remaining lease term was 6.4 years and the weighted-average discount rate was 5.38%.

Operating leases mature as follows (in thousands):

Fiscal Year Ended December 31,	Minimum Payments
2023	$	20,721
2024	18,973
2025	16,254
2026	13,537
2027	11,451
Thereafter	27,733
Total lease payments	108,669
Less: interest	(19,861)
Present value of lease liabilities	$	88,808

During the three months ended March 31, 2023, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow of $3.3 million related to increases in the operating lease right-of-use assets and operating lease liabilities, respectively. As of March 31, 2023, the Company did not have any significant operating or financing leases that had not yet commenced.

LEASES

LEASES

During the three months ended March 31, 2023 and 2022, the Company incurred operating lease expenses of $7.0 million and $7.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of March 31, 2023, the weighted-average remaining lease term was 6.4 years and the weighted-average discount rate was 5.38%.

Operating leases mature as follows (in thousands):

Fiscal Year Ended December 31,	Minimum Payments
2023	$	20,721
2024	18,973
2025	16,254
2026	13,537
2027	11,451
Thereafter	27,733
Total lease payments	108,669
Less: interest	(19,861)
Present value of lease liabilities	$	88,808

During the three months ended March 31, 2023, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow of $3.3 million related to increases in the operating lease right-of-use assets and operating lease liabilities, respectively. As of March 31, 2023, the Company did not have any significant operating or financing leases that had not yet commenced.

XML

PROPERTY AND EQUIPMENT

3 Months Ended

Mar. 31, 2023

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT

Property and equipment was as follows as of March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Infusion pumps	$	35,500	$	34,942
Equipment, furniture and other	35,156		31,929
Leasehold improvements	99,639		99,085
Computer software, purchased and internally developed	44,035		34,922
Assets under development	18,992		29,411
	233,322		230,289
Less: accumulated depreciation	(127,751)		(121,968)
Property and equipment, net	$	105,571	$	108,321

Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March 31, 2023 and 2022 (in thousands):

	Three Months Ended March 31,
	2023		2022
Depreciation expense in cost of revenue	$	711	$	1,257
Depreciation expense in operating expenses	6,012		7,188
Total depreciation expense	$	6,723	$	8,445

XML

GOODWILL AND OTHER INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the carrying amount of goodwill consists of the following activity for the three months ended March 31, 2023 (in thousands):

Balance at December 31, 2022	$	1,533,424
Purchase accounting adjustments	145
Balance at March 31, 2023	$	1,533,569

The carrying amount and accumulated amortization of intangible assets consist of the following as of March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Gross intangible assets:
Referral sources	$	509,646	$	509,646
Trademarks/names	38,508		38,508
Other amortizable intangible assets	912		912
Total gross intangible assets	549,066		549,066
Accumulated amortization:
Referral sources	(175,645)		(167,902)
Trademarks/names	(17,548)		(16,901)
Other amortizable intangible assets	(195)		(148)
Total accumulated amortization	(193,388)		(184,951)
Total intangible assets, net	$	355,678	$	364,115

Amortization expense for intangible assets was $8.5 million and $7.5 million for the three months ended March 31, 2023 and 2022, respectively.

XML

INDEBTEDNESS

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

INDEBTEDNESS

INDEBTEDNESS

Long-term debt consisted of the following as of March 31, 2023 (in thousands):

	Principal Amount		Discount		Debt Issuance Costs		Net Balance
Asset-based-lending (“ABL”) Facility	$	—	$	—	$	—	$	—
First Lien Term Loan	592,500		(7,982)		(11,077)		573,441
Senior Notes	500,000		—		(9,654)		490,346
	$	1,092,500	$	(7,982)	$	(20,731)	1,063,787
Less: current portion							(6,000)
Total long-term debt							$	1,057,787

Long-term debt consisted of the following as of December 31, 2022 (in thousands):

	Principal Amount		Discount		Debt Issuance Costs		Net Balance
ABL Facility	$	—	$	—	$	—	$	—
First Lien Term Loan	594,000		(8,307)		(11,529)		574,164
Senior Notes	500,000		—		(9,960)		490,040
	$	1,094,000	$	(8,307)	$	(21,489)	1,064,204
Less: current portion							(6,000)
Total long-term debt							$	1,058,204

The interest rate on the First Lien Term Loan was 7.38% and 6.82% as of March 31, 2023 and December 31, 2022, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 7.28% and 3.25% for the three months ended March 31, 2023 and 2022, respectively. The interest rate on the Senior Notes was 4.375% as of March 31, 2023 and December 31, 2022. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three months ended March 31, 2023 and 2022.

Long-term debt matures as follows (in thousands):

Fiscal Year Ended December 31,	Minimum Payments
2023	$	4,500
2024	6,000
2025	6,000
2026	6,000
2027	6,000
Thereafter	1,064,000
Total	$	1,092,500

During the three months ended March 31, 2023 and 2022, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 11, Derivative Instruments, for further discussion.

The following table presents the estimated fair values of the Company’s debt obligations as of March 31, 2023 (in thousands):

Financial Instrument	Carrying Value as of March 31, 2023		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
First Lien Term Loan	$	573,441	$	—	$	590,278	$	—
Senior Notes	490,346		—		441,250		—
Total debt instruments	$	1,063,787	$	—	$	1,031,528	$	—

See Note 12, Fair Value Measurements, for further discussion.

Effective January 13, 2023, the Company entered into an agreement to amend the ABL Facility, to among other things, increase the amount of borrowing availability by $50.0 million to $225.0 million total borrowing availability and to replace LIBOR with Secured Overnight Financing Rate (“SOFR”) as the new reference rate.

XML

DERIVATIVE INSTRUMENTS

3 Months Ended

Mar. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE INSTRUMENTS

DERIVATIVE INSTRUMENTS

The Company uses derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to increases in interest rates related to its variable interest rate debt. Use of derivative financial instruments in hedging programs subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. In a hedging relationship, the change in the value of the derivative financial instrument is offset to a great extent by the change in the value of the underlying hedged item. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.

In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300 million for a 5-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan’s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.

The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):

	Fair Value - Derivatives in Asset Position
Derivative	Balance Sheet Caption	March 31, 2023		December 31, 2022
Interest rate cap designated as cash flow hedge	Prepaid expenses and other current assets	$	9,939	$	10,926
Interest rate cap designated as cash flow hedge	Other noncurrent assets	13,734		17,342
Total derivative assets		$	23,673	$	28,268

The gain (loss) associated with the change in the fair value of the effective portion of the hedging instrument is recorded in other comprehensive (loss) income. The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):

	Three Months Ended March 31,
Derivative	2023		2022
Interest rate cap designated as cash flow hedge	$	(4,595)	$	14,833

The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):

		Three Months Ended March 31,
Derivative	Income Statement Caption	2023		2022
Interest rate cap designated as cash flow hedge	Interest expense, net	$	2,352	$	694

XML

FAIR VALUE MEASURMENTS

3 Months Ended

Mar. 31, 2023

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:

•Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.

•Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.

•Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.

While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.

Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.

Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, Derivative Instruments, for further discussion of the fair value of the interest rate cap.

Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).

There were no other assets or liabilities measured at fair value at March 31, 2023 and December 31, 2022.

XML

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.

The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s condensed consolidated balance sheets.

However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.

XML

STOCK-BASED INCENTIVE COMPENSATION	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
STOCK-BASED INCENTIVE COMPENSATION	STOCK-BASED INCENTIVE COMPENSATIONEquity Incentive Plans — Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the BioScrip stockholders on May 3, 2018 and amended and restated on May 19, 2021, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors, resulting in a total of 9,101,734 shares of common stock authorized for issuance. The 2018 Plan is administered by the Company’s Compensation Committee, a standing committee of the Company’s Board of Directors. The Company had stock options, restricted stock units and performance stock units outstanding related to the 2018 Plan as of March 31, 2023 and 2022. During the three months ended March 31, 2023 and 2022, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $6.0 million and $4.2 million.

XML

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2023

Equity [Abstract]

STOCKHOLDERS’ EQUITY

STOCKHOLDERS’ EQUITY

2017 Warrants — During the three months ended March 31, 2023 and 2022, warrant holders did not elect to exercise any warrants to purchase shares of common stock. As of March 31, 2023 and December 31, 2022, the remaining warrant holders are entitled to purchase 240,188 shares of common stock.

2015 Warrants — During the three months ended March 31, 2023 and 2022, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. As of March 31, 2023 and December 31, 2022, the remaining warrant holders are entitled to purchase 15,219 and 15,231 shares of common stock, respectively.

Share Repurchase Program — On February 20, 2023, the Company’s Board of Directors approved a share repurchase program of up to an aggregate $250.0 million of common stock of the Company. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.

On March 3, 2023, the Company purchased 2,475,166 shares of common stock under the share repurchase program for an average share price of $30.30, totaling $75.0 million, which repurchased shares became treasury stock. As of March 31, 2023, the Company is authorized to repurchase up to an aggregate $175.0 million of common stock of the Company.

XML

RELATED-PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2023

Related Party Transactions [Abstract]

RELATED-PARTY TRANSACTIONS

RELATED-PARTY TRANSACTIONS

Transactions with Equity-Method Investees — The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $1.3 million and $0.9 million for the three months ended March 31, 2023 and 2022, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income. During the three months ended March 31, 2023, the Company received distributions from the investees of $2.5 million. During the three months ended March 31, 2022, the Company did not receive a distribution from the investees.

The Company had amounts due from its joint ventures of $0.7 million and due to its joint ventures of $0.5 million as of March 31, 2023. Receivables were included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. The Company also had amounts due to its joint ventures of $1.5 million as of December 31, 2022. These payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.

Share Repurchase Agreement — On February 28, 2023, we entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) with HC I, pursuant to which we agreed to repurchase, subject to the terms and conditions contained therein, up to $75.0 million of our common stock then held by HC I at the same purchase price per share as the underwriter in a concurrent underwritten public offering of our common stock held by HC I. On March 3, 2023, the transactions contemplated by the Share Repurchase Agreement closed, and we repurchased directly from HC I 2,475,166 shares of our common stock.

XML

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2023

Subsequent Events [Abstract]

Subsequent Events

SUBSEQUENT EVENTSOn May 3, 2023 the Company entered into a definitive merger agreement with Amedisys, Inc. (“Amedisys”), a leading provider of healthcare in home health and hospice settings. Under the terms of the merger agreement, the Company will issue new shares of its common stock to Amedisys’s stockholders, which will result in the Company’s stockholders holding

approximately 64.5% of the combined company. Following the close of the transaction, the combined company common stock is expected to continue to be listed on the Nasdaq Global Select Market. The transaction is currently expected to close in the second half of 2023, subject to approval by the Company’s and Amedisys’s stockholders and other customary closing conditions, including receipt of applicable regulatory approvals.

In connection with its entry into the merger agreement, the Company entered into a debt commitment letter, dated as of May 3, 2023, with Goldman Sachs Bank USA ("Goldman Sachs"), pursuant to which Goldman Sachs has committed to provide a 364-day senior secured term loan facility in an aggregate principal amount of up to $450 million (the "Bridge Loan Facility"), subject to customary conditions as set forth therein. The debt commitment letter provides for a single borrowing of non-amortizing terms loans under such Bridge Loan Facility in an amount up to $450.0 million, which term loans would mature on the date that is 364 days following execution of the definition documentation in respect thereof. The net proceeds of the Bridge Loan Facility may be used to refinance existing indebtedness of Amedisys and to pay related fees and expenses.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2022 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.

Principles of Consolidation

Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.

Cash and Cash Equivalents

Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of March 31, 2023, cash equivalents consisted of money market funds.

Equity Method Investments

Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of March 31, 2023 and December 31, 2022, the balance of the investments was $18.3 million and $19.4 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.4 million and $1.3 million for the three months ended March 31, 2023 and 2022, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three months ended March 31, 2023, the Company received a distribution of $2.5 million from the investees. During the three months ended March 31, 2022, the Company did not receive a distribution from the investees. See Note 16, Related-Party Transactions, for discussion of related-party transactions with these investees.

Concentrations of Business Risk

Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 14% and 15% for the three months ended March 31, 2023 and 2022, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.

For the three months ended March 31, 2023 and 2022, approximately 12% and 13%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. As of March 31, 2023 and December 31, 2022, approximately 11% and 13%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.

The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.

For the three months ended March 31, 2023 and 2022, approximately 72% and 75%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results. Although there remains some uncertainty regarding the COVID-19 pandemic, as of March 31, 2023, the Company has been able to maintain adequate levels of supplies and pharmaceuticals to support its operations.

Fair Value Measurements

FAIR VALUE MEASUREMENTS

Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:

•Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.

•Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.

•Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.

While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.

Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 10, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.

Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, Derivative Instruments, for further discussion of the fair value of the interest rate cap.

Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).

XML

BUSINESS COMBINATIONS (Tables)

3 Months Ended

Mar. 31, 2023

Business Combination and Asset Acquisition [Abstract]

Schedule of Acquired Identifiable Assets and Assumed Liabilities

The following is a final allocation of the consideration transferred to acquired identifiable assets and assumed liabilities, net of cash acquired, as of March 31, 2023 (in thousands):

	Amount
Accounts receivable	$	686
Intangible assets	5,449
Other assets	394
Accounts payable and other liabilities	(434)
Fair value identifiable assets and liabilities	6,095
Goodwill (1)	21,323
Cash acquired	201
Purchase price	27,619
Less: cash acquired	(201)
Purchase price, net of cash acquired	$	27,418

(1) Goodwill is attributable to cost synergies from procurement and operational efficiencies and elimination of duplicative administrative costs.

XML

REVENUE (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Net Revenue Earned by Category of Payer

The following table sets forth the net revenue earned by category of payer for the three months ended March 31, 2023 and 2022 (in thousands):

	Three Months Ended March 31,
	2023		2022
Commercial payers	$	873,911	$	786,278
Government payers	122,789		115,205
Patients	19,148		14,301
Net revenue	$	1,015,848	$	915,784

XML

EARNINGS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Earnings Per Share

The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):

	Three Months Ended March 31,
	2023		2022
Numerator:
Net income	$	39,208	$	30,275
Denominator:
Weighted average number of common shares outstanding	181,262		179,961
Earnings per common share:
Earnings per common share, basic	$	0.22	$	0.17

The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):

	Three Months Ended March 31,
	2023		2022
Numerator:
Net income	$	39,208	$	30,275
Denominator:
Weighted average number of common shares outstanding	181,262		179,961
Effect of dilutive securities	1,473		1,720
Weighted average number of common shares outstanding, diluted	182,735		181,681
Earnings per common share:
Earnings per common share, diluted	$	0.21	$	0.17

XML

LEASES (Tables)

3 Months Ended

Mar. 31, 2023

Leases [Abstract]

Schedule of Maturities of Lease Liabilities, Operating

Operating leases mature as follows (in thousands):

Fiscal Year Ended December 31,	Minimum Payments
2023	$	20,721
2024	18,973
2025	16,254
2026	13,537
2027	11,451
Thereafter	27,733
Total lease payments	108,669
Less: interest	(19,861)
Present value of lease liabilities	$	88,808

XML

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2023

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment was as follows as of March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Infusion pumps	$	35,500	$	34,942
Equipment, furniture and other	35,156		31,929
Leasehold improvements	99,639		99,085
Computer software, purchased and internally developed	44,035		34,922
Assets under development	18,992		29,411
	233,322		230,289
Less: accumulated depreciation	(127,751)		(121,968)
Property and equipment, net	$	105,571	$	108,321

The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three months ended March 31, 2023 and 2022 (in thousands):

	Three Months Ended March 31,
	2023		2022
Depreciation expense in cost of revenue	$	711	$	1,257
Depreciation expense in operating expenses	6,012		7,188
Total depreciation expense	$	6,723	$	8,445

XML

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of the Carrying Amount of Goodwill

Changes in the carrying amount of goodwill consists of the following activity for the three months ended March 31, 2023 (in thousands):

Balance at December 31, 2022	$	1,533,424
Purchase accounting adjustments	145
Balance at March 31, 2023	$	1,533,569

Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets

The carrying amount and accumulated amortization of intangible assets consist of the following as of March 31, 2023 and December 31, 2022 (in thousands):

	March 31, 2023		December 31, 2022
Gross intangible assets:
Referral sources	$	509,646	$	509,646
Trademarks/names	38,508		38,508
Other amortizable intangible assets	912		912
Total gross intangible assets	549,066		549,066
Accumulated amortization:
Referral sources	(175,645)		(167,902)
Trademarks/names	(17,548)		(16,901)
Other amortizable intangible assets	(195)		(148)
Total accumulated amortization	(193,388)		(184,951)
Total intangible assets, net	$	355,678	$	364,115

XML

INDEBTEDNESS (Tables)

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

Schedule of Debt

Long-term debt consisted of the following as of March 31, 2023 (in thousands):

	Principal Amount		Discount		Debt Issuance Costs		Net Balance
Asset-based-lending (“ABL”) Facility	$	—	$	—	$	—	$	—
First Lien Term Loan	592,500		(7,982)		(11,077)		573,441
Senior Notes	500,000		—		(9,654)		490,346
	$	1,092,500	$	(7,982)	$	(20,731)	1,063,787
Less: current portion							(6,000)
Total long-term debt							$	1,057,787

Long-term debt consisted of the following as of December 31, 2022 (in thousands):

	Principal Amount		Discount		Debt Issuance Costs		Net Balance
ABL Facility	$	—	$	—	$	—	$	—
First Lien Term Loan	594,000		(8,307)		(11,529)		574,164
Senior Notes	500,000		—		(9,960)		490,040
	$	1,094,000	$	(8,307)	$	(21,489)	1,064,204
Less: current portion							(6,000)
Total long-term debt							$	1,058,204

Schedule of Long-term Debt Maturities

Long-term debt matures as follows (in thousands):

Fiscal Year Ended December 31,	Minimum Payments
2023	$	4,500
2024	6,000
2025	6,000
2026	6,000
2027	6,000
Thereafter	1,064,000
Total	$	1,092,500

Schedule of Estimated Fair Values of Debt Obligations

The following table presents the estimated fair values of the Company’s debt obligations as of March 31, 2023 (in thousands):

Financial Instrument	Carrying Value as of March 31, 2023		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
First Lien Term Loan	$	573,441	$	—	$	590,278	$	—
Senior Notes	490,346		—		441,250		—
Total debt instruments	$	1,063,787	$	—	$	1,031,528	$	—

XML

DERIVATIVE INSTRUMENTS (Tables)

3 Months Ended

Mar. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Amount and Location of Derivatives in the Balance Sheet

The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):

	Fair Value - Derivatives in Asset Position
Derivative	Balance Sheet Caption	March 31, 2023		December 31, 2022
Interest rate cap designated as cash flow hedge	Prepaid expenses and other current assets	$	9,939	$	10,926
Interest rate cap designated as cash flow hedge	Other noncurrent assets	13,734		17,342
Total derivative assets		$	23,673	$	28,268

Schedule of Pre-tax Gains (Losses) Recognized in the Statements of Comprehensive Income (Loss)

The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):

	Three Months Ended March 31,
Derivative	2023		2022
Interest rate cap designated as cash flow hedge	$	(4,595)	$	14,833

The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):

		Three Months Ended March 31,
Derivative	Income Statement Caption	2023		2022
Interest rate cap designated as cash flow hedge	Interest expense, net	$	2,352	$	694

XML

NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)		3 Months Ended
	Mar. 03, 2023 shares	Mar. 31, 2023 pharmacy suite segment shares
Business Acquisition [Line Items]
Treasury stock, shares, acquired (in shares)	2,475,166
Number of service locations | pharmacy		95
Number of infusion sites | suite		73
Number of operating segments | segment		1
Common Stock | Secondary Offering
Business Acquisition [Line Items]
Number of shares issued in transaction (in shares)		13,000,000
HC Group Holdings I, LLC
Business Acquisition [Line Items]
Percentage of outstanding common stock		0.06
Legacy Health Systems
Business Acquisition [Line Items]
Ownership interest		50.00%

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Concentration Risk [Line Items]
Rebate receivable	$ 48,300		$ 53,400
Investments in equity-method investees	18,300		$ 19,400
Proportionate share of earnings in equity-method investees	1,437	$ 1,267
Proceeds from Equity Method Investment, Distribution	$ 2,500	$ 0
Revenue from Contract with Customer Benchmark | Company's Largest Payer | Largest Payer
Concentration Risk [Line Items]
Concentration ​risk	14.00%	15.00%
Revenue from Contract with Customer Benchmark | Governmental Healthcare Programs | Government Healthcare Programs
Concentration Risk [Line Items]
Concentration ​risk	12.00%	13.00%
Accounts Receivable, Benchmark | Governmental Healthcare Programs | Government Healthcare Programs
Concentration Risk [Line Items]
Concentration ​risk	11.00%		13.00%
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors | Four Vendors
Concentration Risk [Line Items]
Concentration ​risk	72.00%	75.00%

XML

BUSINESS COMBINATIONS - Additional Information (Details) - Rochester Home Infusion, Inc $ in Millions	1 Months Ended
	Aug. 31, 2022 USD ($)
Business Acquisition [Line Items]
Percentage of the combined company held	100.00%
Purchase price, net of cash acquired	$ 27.4

XML

BUSINESS COMBINATIONS - Preliminary Estimate of the Allocation Consideration Transferred (Details) - USD ($) $ in Thousands	1 Months Ended
	Aug. 31, 2022	Mar. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill		$ 1,533,569	$ 1,533,424
Rochester Home Infusion, Inc
Business Acquisition [Line Items]
Accounts receivable	$ 686
Intangible assets	5,449
Other assets	394
Accounts payable and other liabilities	(434)
Fair value identifiable assets and liabilities	6,095
Goodwill	21,323
Cash acquired	201
Purchase price	27,619
Purchase price, net of cash acquired	$ 27,418

XML

REVENUE - Net Revenue Earned by Category of Payer (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Net revenue	$ 1,015,848	$ 915,784
Commercial payers
Disaggregation of Revenue [Line Items]
Net revenue	873,911	786,278
Government payers
Disaggregation of Revenue [Line Items]
Net revenue	122,789	115,205
Patients
Disaggregation of Revenue [Line Items]
Net revenue	$ 19,148	$ 14,301

XML

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ 15,021	$ 10,993
Effective tax rate	27.70%	26.60%
Valuation allowance	$ 13,100

XML

EARNINGS PER SHARE - Additional Information (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	871,491	770,303
Restricted Stock Award
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	342,894	269,670
Performance Stock Unit
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	90,159
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)		457,752

XML

EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator:
Net income	$ 39,208	$ 30,275
Denominator:
Weighted average number of common shares outstanding (in shares)	181,262	179,961
Effect of dilutive securities (in shares)	1,473	1,720
Weighted average number of common shares outstanding, diluted (in shares)	182,735	181,681
Earnings per common share, basic
Earnings per common share, basic (in dollars per share)	$ 0.22	$ 0.17
Earnings per common share, diluted
Earnings per common share, diluted (in dollars per share)	$ 0.21	$ 0.17

XML

LEASES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases [Abstract]
Operating lease cost	$ 7.0	$ 7.3
Weighted-average remaining lease term, operating leases	6 years 4 months 24 days
Weighted-average discount rate, operating leases	5.38%
Increase in operating lease right-of-use asset and lease liabilities	$ 3.3

XML

LEASES - Maturities of Lease Liabilities (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Minimum Payments
2023	$ 20,721
2024	18,973
2025	16,254
2026	13,537
2027	11,451
Thereafter	27,733
Total lease payments	108,669
Less: interest	(19,861)
Present value of lease liabilities	$ 88,808

XML

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 233,322		$ 230,289
Less: accumulated depreciation	(127,751)		(121,968)
Property and equipment, net	105,571		108,321
Total depreciation expense	6,723	$ 8,445
Depreciation expense in cost of revenue
Property, Plant and Equipment [Line Items]
Total depreciation expense	711	1,257
Depreciation expense in operating expenses
Property, Plant and Equipment [Line Items]
Total depreciation expense	6,012	$ 7,188
Infusion pumps
Property, Plant and Equipment [Line Items]
Property and equipment, gross	35,500		34,942
Equipment, furniture and other
Property, Plant and Equipment [Line Items]
Property and equipment, gross	35,156		31,929
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	99,639		99,085
Computer software, purchased and internally developed
Property, Plant and Equipment [Line Items]
Property and equipment, gross	44,035		34,922
Assets under development
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 18,992		$ 29,411

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill - net book value, begging of period	$ 1,533,424
Purchase accounting adjustments	145
Goodwill - net book value, end of period	$ 1,533,569

XML

GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	$ 549,066		$ 549,066
Total accumulated amortization	(193,388)		(184,951)
Total intangible assets, net	355,678		364,115
Amortization expense for intangible assets	8,500	$ 7,500
Referral sources
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	509,646		509,646
Total accumulated amortization	(175,645)		(167,902)
Trademarks/names
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	38,508		38,508
Total accumulated amortization	(17,548)		(16,901)
Other amortizable intangible assets
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	912		912
Total accumulated amortization	$ (195)		$ (148)

XML

INDEBTEDNESS - Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal Amount	$ 1,092,500	$ 1,094,000
Discount	(7,982)	(8,307)
Debt Issuance Costs	(20,731)	(21,489)
Net Balance	1,063,787	1,064,204
Less: current portion	(6,000)	(6,000)
Total long-term debt	1,057,787	1,058,204
Senior Notes | First Lien Term Loan
Debt Instrument [Line Items]
Principal Amount	592,500	594,000
Discount	(7,982)	(8,307)
Debt Issuance Costs	(11,077)	(11,529)
Net Balance	573,441	574,164
Senior Notes | Senior Notes
Debt Instrument [Line Items]
Principal Amount	500,000	500,000
Discount	0	0
Debt Issuance Costs	(9,654)	(9,960)
Net Balance	490,346	490,040
Senior Notes | Asset-based-lending (“ABL”) Facility
Debt Instrument [Line Items]
Principal Amount	0	0
Discount	0	0
Debt Issuance Costs	0	0
Net Balance	$ 0	$ 0

XML

INDEBTEDNESS - Additional Information (Details) - Senior Notes - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jan. 13, 2023	Dec. 31, 2022
Asset-based-lending (“ABL”) Facility
Debt Instrument [Line Items]
Credit facility, borrowing availability			$ 225.0	$ 50.0
First Lien Term Loan | Credit Agreements Amendment
Debt Instrument [Line Items]
Effective rate on term loans at end of period	7.38%			6.82%
Weighted average interest rate paid on term loans during period	7.28%	3.25%
Second Lien Term Loan | Credit Agreements Amendment
Debt Instrument [Line Items]
Effective rate on term loans at end of period	4.375%			4.375%
Weighted average interest rate paid on term loans during period	4.375%	4.375%

XML

INDEBTEDNESS - Long Term Debt Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
2023	$ 4,500
2024	6,000
2025	6,000
2026	6,000
2027	6,000
Thereafter	1,064,000
Total	$ 1,092,500	$ 1,094,000

XML

INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Debt Instrument [Line Items]
Total debt instruments	$ 1,063,787
Markets for Identical Item (Level 1)
Debt Instrument [Line Items]
Total debt instruments	0
Significant Other Observable Inputs (Level 2)
Debt Instrument [Line Items]
Total debt instruments	1,031,528
Significant Unobservable Inputs (Level 3)
Debt Instrument [Line Items]
Total debt instruments	0
Senior Notes
Debt Instrument [Line Items]
Total debt instruments	490,346
Senior Notes | First Lien Term Loan
Debt Instrument [Line Items]
Total debt instruments	573,441
Senior Notes | Markets for Identical Item (Level 1)
Debt Instrument [Line Items]
Total debt instruments	0
Senior Notes | Markets for Identical Item (Level 1) | First Lien Term Loan
Debt Instrument [Line Items]
Total debt instruments	0
Senior Notes | Significant Other Observable Inputs (Level 2)
Debt Instrument [Line Items]
Total debt instruments	441,250
Senior Notes | Significant Other Observable Inputs (Level 2) | First Lien Term Loan
Debt Instrument [Line Items]
Total debt instruments	590,278
Senior Notes | Significant Unobservable Inputs (Level 3)
Debt Instrument [Line Items]
Total debt instruments	0
Senior Notes | Significant Unobservable Inputs (Level 3) | First Lien Term Loan
Debt Instrument [Line Items]
Total debt instruments	$ 0

XML

DERIVATIVE INSTRUMENTS - Additional Information (Details) - Interest Rate Cap - First Lien Term Loan - Designated as Hedging Instrument - Senior Notes	1 Months Ended
	Oct. 31, 2021 USD ($)
Derivative [Line Items]
Notional amount of derivative	$ 300,000,000
Derivative, term of contract	5 years

XML

DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Derivative asset	$ 23,673	$ 28,268
Designated as Hedging Instrument | Prepaid expenses and other current assets | Interest Rate Cap
Derivative [Line Items]
Derivative asset	9,939	10,926
Designated as Hedging Instrument | Other noncurrent assets | Interest Rate Cap
Derivative [Line Items]
Derivative asset	$ 13,734	$ 17,342

XML

DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) - Interest Rate Cap - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Derivative [Line Items]
Interest rate cap designated as cash flow hedge	$ (4,595)	$ 14,833
Interest expense, net
Derivative [Line Items]
Interest rate cap designated as cash flow hedge	$ 2,352	$ 694

XML

STOCK-BASED INCENTIVE COMPENSATION (Details) - 2018 Plan - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	May 03, 2018
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)			9,101,734
HC I Incentive Units
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense	$ 6.0	$ 4.2

XML

STOCKHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended
	Mar. 03, 2023	Mar. 31, 2023	Mar. 31, 2022	Feb. 20, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Treasury stock, shares, acquired (in shares)	2,475,166
Treasury stock acquired, average cost per share (in dollars per share)	$ 30.30
Shares repurchased	$ 75.0
Stock repurchase program, authorized amount		$ 175.0
Common Stock
Class of Warrant or Right [Line Items]
Number of shares authorized to be repurchased (in shares)				250,000,000
Common Stock | 2017 Warrants
Class of Warrant or Right [Line Items]
Number of warrants exercisable (in shares)		0	0
Class of warrant or right, outstanding (in shares)		240,188			240,188
Common Stock | 2015 Warrants
Class of Warrant or Right [Line Items]
Class of warrant or right, outstanding (in shares)		15,219			15,231

XML

RELATED-PARTY TRANSACTIONS (Details) - USD ($) $ in Thousands		3 Months Ended
	Mar. 03, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Proceeds from Equity Method Investment, Distribution		$ 2,500	$ 0
Shares repurchased	$ 75,000
Treasury stock, shares, acquired (in shares)	2,475,166
Joint Venture
Related Party Transaction [Line Items]
Management fee income		1,300	$ 900
Proceeds from Equity Method Investment, Distribution		2,500
Due from joint venture		700
Due to Related Parties		$ 500		$ 1,500

XML

SUBSEQUENT EVENTS - Narrative (Details) - Subsequent Event - Amedisys $ in Millions	May 03, 2023 USD ($)
Subsequent Event [Line Items]
Term loan facility, maturity term	364 days
Combined company, following merger
Subsequent Event [Line Items]
Company's stockholders, ownership percentage following merger	64.50%
Senior Notes
Subsequent Event [Line Items]
Term loan facility, maximum borrowing capacity	$ 450.0